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ABSTRACT 	  	  	  
Molecular and genetic technology has been essential to answer critical questions 
in molecular biology.  Although many important questions must be answered in 
molecular biology, advanced molecular tools are yet to be available to answer those 
critical questions. This thesis describes the development of new genetic tools and their 
applications.  First, the attempt of developing a new genetic technology termed 
chromosome translocation technology is described.  The chromosome translocation 
technology is a genetic tool that allows us to transfer a large fragment of chromosome 
between species.  A canine quantitative trait locus (QTL) that determines the length and 
width of femur is used as my model case and transfers this canine QTL to mouse 
embryonic stem (ES) cells to recapitulate the skeletal phenotype observed in dogs and 
further characterize this locus in mice. Later, application of piggyback DNA transposon 
system as a mutagenesis tool and characterization of a novel gene AK045681 in mouse 
from the mutagenesis screen are described.  Amino acid sequence similarity of 
AK045681 to the spliceosomal protein U1C suggested the biological function of this 
novel gene might be RNA splicing.  Double immunostaining showed the co-localization 
of AK045681 to a core component of the spliceosome SmB/B’/N, which indicated that 
AK045681 might be a part of the spliceosome.  Expression of this novel gene began 
postnatally and continued in aulthood.  AK045681 was mainly expressed in GABAergic 
neurons in the neural regions that were known to regulate fear or anxiety including the
	   iv	  
hippocampus, the amygdala, the basal ganglia and the cortex. Behavioral analyses further 
revealed that AK045681 knockout mice showed reduced fear or anxiety in the elevated 
plus maze and dark-light transition task.  The results suggested that AK045681 played a 
role in the regulation of anxiety (fear) in mice.  AK045681 was now named Sango 
(meaning after birth in Japanese) after the postnatal-specific expression of the gene.  
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Molecular and genetic technology has been essential to answer critical questions 
in biology.  Though many important biological questions must be answered, the 
necessary technological advances are yet limited and the new invention of molecular 
technologies are long awaited.  A goal of this thesis is to describe the challenges in 
developing new genetic tools and their application. The first half of my thesis describes 
the attempt to develop a technology (chromosome translocation) that allows us to transfer 
a large fragment of chromosome between species.  A canine quantitative trait locus 
(QTL) that determines the length and width of femur is used as my model and transfers 
this canine QTL to mouse embryonic stem (ES) cells to recapitulate the skeletal 
phenotype observed in dogs and further characterize this locus in mice. To achieve 
chromosome translocation between species, gene targeting as well as a novel technology, 
iPSC technology (induced Pluripotent Stem Cell) pioneered by Sinya Yamanaka were 
utilized as a part of the strategy (Takahashi & Yamanaka, 2006).  DNA transposons like 
piggyBac transposons have been shown to be an effective genetic tool for insertion 
mutagenesis in invertebrates.  Recently, piggyBac transposons have shown their high 
mutagenesis efficiency in vertebrates such as mice.   However, detailed phenotypic 
analyses of the mutant mice from the piggyBac mutagenesis have rarely been performed.  
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The second half of my thesis presents successful application of piggybac DNA 
transposon system that has led me to characterize a novel gene locus AK045681 in mice.  
In this chapter, mechanisms and applications of three genetic tools, gene targeting, iPSC 
technology and piggyBac DNA transposons are reviewed.   
 
Gene targeting and Cre-Lox recombinase system 
Gene targeting by homologous recombination in mammalian cells has 
undoubtedly revolutionized science.  The basic principle of gene targeting is that the 
incoming DNA includes a portion with the same nucleotide sequence as a portion in the 
targeting gene, therefore enabling homologous recombination between them (Lewin, 
2004).  Significantly, gene targeting offers the specificity for introducing mutation in 
mice.  With the sequenced genomes such as mice and humans, a specific gene of interest 
can be altered in any way desired.  Additionally, gene targeting allows researchers to gain 
full control of how to manipulate the gene of interest, and thus give the researchers an 
opportunity to devise the best genetic modification (e.g., generation of null mutation, 
reporter allele for cell lineage analysis or tissue-specific Cre-expressing allele for tissue-
specific gene inactivation) of the chosen gene to answer a specific biological question 
(Capecchi, 2001, 2005; Koller & Smithies, 1992).   
Gene targeting in mice was pioneered independently by Mario Capecchi and 
Oliver Smithies following discovery of the mouse embryonic stem cell lines by Martin 
Evans (Koller & Smithies, 1992).  Hereupon, I focus on the Capecchi’s work to describe 
the development of gene targeting. While he was developing a microinjection method as 
a DNA delivery method into the nuclei of mammalian cells, he observed the multiple 
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copies of injected DNA sequences were integrated as a highly ordered head to tail 
concatemer into nuclei of the mammalian cultured cells upon an injection of multiple 
copies of DNA plasmid (i.e., HSV-tk plasmids) into cells (Capecchi, 2001, 2005).  He 
hypothesized that the highly ordered concatemers should be created in highly regulated 
fashions such as homologous recombination in cells, and later his laboratory 
demonstrated that homologous recombination indeed generated those head-to-tail 
concatemers in the nuclei of mouse fibroblasts and mammalian cells were equipped with 
an efficient enzymatic machinery to perform homologous recombination between newly 
introduced exogenous DNAs (Folger et al., 1982; Capecchi, 2001, 2005).   
Following this major success, Capecchi and colleagues ultimately deactivate or 
“knockout” the endogenous hypoxanthine phosphoribosyl transferase (Hprt1) gene by 
replacing exon 8 of Hprt1 with Neomycin resistance gene (Neor ) through homologous 
recombination in mouse ES cells (Thomas and Capecchi, 1987).  Their targeting strategy 
of Hprt1 was ingenious for two reasons.  First, Hprt1 gene is located in the X-
chromosome, and their mouse ES cell lines were isolated from a male mouse.  Thus, gene 
targeting could easily generate Hprt1 null cell lines by simply disrupting a single copy of 
the Hprt1 gene.  Second, his group exploited the drug selection scheme by 6-thioguanine 
(6TG), which kills cells with a functional Hprt1 locus (Szybalski, 1992).  This is the 
prelude for invention of the enrichment scheme of gene targeting known as the positive-
negative selection, which is Cappechi’s other significant contribution to gene targeting 
technology.  His laboratory ultimately perfected the positive-negative selection scheme.  
In his design he engineered Neor gene into his targeting vector, and linked the herpes 
virus thymidine kinase gene (HVS-tk) to one or both of his targeting vector as positive 
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and negative selection, respectively.   The Neor gene was used to ”positively” select for 
the recipient cells that have integrated the targeting vector into the genome whereas the 
drug selection by FIAU or ganciclovir, which kills the cells containing a functional HSV-
tk gene, selected against (negatively) the cells that have randomly incorporated the 
targeting vector.  Thus, this positive-negative selection scheme dramatically improved a 
chance to obtain ES cell lines with a properly targeted locus of their choice.  Reportedly, 
enrichment of properly targeted ES cells after double selection with G418 and ganciclovir 
was two thousand times greater than after single selection of G418 (Mansour et al., 
1988).  To identify correctly targeted cells among the transfected cells requires 
researchers to screen as many as 10,000 transfected cells.  Thus, the enrichment scheme 
by positive-negative selection has been extremely beneficial and now is routinely utilized 
(Koller & Smithies, 1992). Recently, new negative selectable genes such as diphtheria 
toxin A (DT-A) fragment (DT-A) have been used for a negative selection and shown to 
be as effective as HSV-tk gene (Araki et al., 2006).         
Undeniably, gene targeting by homologous recombination in mice has 
significantly improved our knowledge of mammalian gene function.  However, even this 
technology encounters a number of limitations because genetic modifications introduced 
by homologous recombination are permanent in the germ line, and thus those genetic 
modifications stay in all cells of mice throughout life.  Frequently, a number of genes 
have multiple roles during embryogenesis and adulthood.  Knocking out those genes can 
give rise to an embryonic lethal phenotype, which indicates the earliest nonredundant role 
of the gene, and prevents an analysis of the gene’s function(s) at later stages of 
development.  Some of the phenotypes caused by such a genetic manipulation are 
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difficult to interpret because of cell-autonomous, cell-nonautonomous or systemic effects 
in the whole animal.  Generally, permanent germ line mutations by this technology 
preclude the analysis of gene function in a specific cell type and at given time.  In 
addition, gene targeting by homologous recombination is not apt to engineer complex 
chromosomal alterations, such as large deletions, duplications, inversions and 
translocations) that are often linked to human diseases, and thus is not an optimal 
technique to replicate chromosomal rearrangements that cause human diseases in 
postnatal life as a result of the interaction of somatic mutation and environmental factors 
such as sporadic cancer (Ryding et al., 2001; Lewandoski, 2002; Kwan, 2002; Feil, 
2007).  To circumvent these limitations, a site-specific recombination technology has 
been built on classic gene targeting by homologous recombination technology.  
Site-specific recombination is described by reciprocal exchange between two 
specific DNA recognition sites regulated by a site-specific recombinase, which creates 
integration, excision and inversion of defined DNA fragments.  The site-specific 
recombination system generally consists of a pair of DNA recombination sites 
(approximately 20-200-bps in length) and a specialized site-specific recombinase that 
recognizes, aligns, breaks and rejoins these sites in reciprocal manner (Ryding et al., 
2001;Lewandoski, 2002; Kwan, 2002; Feil, 2007).  The recombination sequences are in 
part asymmetric, conferring directionality to the recombination process.  As a result, the 
outcome of site-specific recombination relies upon the location and relative orientation of 
the recognition sites regarding one another.  If the two sites are on the same DNA 
molecule, recombination between sites that are the reverse direction triggers an inversion 
of the DNA between those two sites; as recombination between the two sites that are in 
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the same direction leads to an excision of the flanked DNA in the form of a circular 
product (Figure 1-1).  If the two sites are on separate DNA molecules, the recombination 
is intermolecular and can generate DNA integration (translocation) (Figure 1-1).  The 
recombination reaction progress through covalent recombinase-DNA intermediates with 
conservation of phosphodiester bond energy.  As DNA topoisomerases functions, site-
specific recombinases break DNA strands by direct phosphoryl transfer to the 
nucleophilic hydroxyl group of a catalytic tyrosine or serine residue.  The cleaved DNA 
strands are joined together to new partners by reversing the process.  In consequence, 
site-specific recombinses pose dual functions of site-specific endonuclease and ligase.  
Site-specific recombinases perform the recombination reaction without co-factors as 
ATP. (Ryding et al., 2001;Lewandoski, 2002; Kwan, 2002; Feil, 2007).   
Cre (causes recombination) recombinase is 38-kDa protein encoded by 
bacteriophages P1.  Cre recombinase directs recombination between two 34-bp target 
recombination sites called loxP (locus of crossing-over [X] of P1) without any co-factor 
(Ryding et al., 2001;Lewandoski, 2002; Kwan, 2002; Feil, 2007).  The loxP sequence is 
composed of two 13-bp inverted repeats separated by an 8-bp asymmetric core region 
that confers overall directionality (Figure 1-1).  One Cre monomer binds to each of the 
palindromes, which facilitates the formation of a synaptic complex of two loxP sites.  
After the cleavage of DNA strands, four Cre molecules exchange and ligate within the 
core regions (Figure 1-2).  It has been demonstrated that this one site-specific 
recombination system works particularly well in mice (Ryding et al., 2001;Lewandoski, 
2002; Kwan, 2002; Feil, 2007).  A classic gene targeting technique is used to generate a 
mouse in which an essential region of a gene of interest is floxed (flanked by loxP) so  











Figure 1-1. Site-specific directional recombination reactions.  Site-specific 
recombinases, such as Cre recobinase, excise a region flanked by the palindromes 
inter- and intramolecularly, which creates deletion, inversion and translocation 










Figure 1- 2. Structure and DNA sequence of the recombinase recognition site loxP 
(Top Panel).  The loxP site is composed of two 13-bp palindromes flanking an 
asymmetric 8-bp core, which define the orientation of the recognition site.  General 
strategy of Cre-mediated tissue-specific inactivation in mice (Bottom Panel) 
(Reprinted with permission from Lewandoski, 2001).	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that crossing with other mice transgenic for Cre recombinase under the control of a 
specific promoter allows time- and tissue-specific deactivation of the floxed region of the 
gene of interest.   
This “conditional” knockout/inactivation of genes ensures that the activity of the 
gene is modified in a limited range of cells at a particular developmental stage, whereas 
the cells in the rest of the animal’s body are genetically unaltered.  Lakso and colleagues 
(1992) first demonstrated that the Cre-regulated activation of SV40 large T antigen 
transgene in lens cell led to tumor formation (Figure 1-2 for general description of tissue-
sepcific KO).  Furthermore, Rajewsky and colleagues further improved the Cre/lox-
mediated tissue-specific recombination (Gu et al., 1994) and inducible recombination in 
mice (Kuhn et al., 1995).  Numerous conditional mouse lines have been made to 
elucidate tissue-specific functions of genes (see Kwan, 2002 for the list of conditional 
mice lines available).   
Cre/lox strategy can be effectively used for cell fate-mapping studies.  Ce/lox-
based cell fate mapping uses reporter mice in which a histological marker can be 
activated by Cre-mediated recombination in nearly any tissue, thus reporting Cre activity.  
The generation of such reporter mouse lines can be accomplished by classic gene 
targeting to Cre-activatable reporter cassette (β-galactosidase, enhanced fluorescent 
protein of green, yellow or cyan varieties) into Rosa26 locus, which generates 
constitutive transgene expression.  Those reporter mice lines are effective for linking 
gene expression to the fate of particular cell lineage because activation of the reporter 
gene by a specific tissue-specific Cre-expressing mouse line suggests that Cre activity is 
present in that particular cell or was present in a progenitor cell (Ryding et al., 2001; 
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Lewandoski, 2002; Kwan, 2002; Feil, 2007).  This approach has been successfully used 
to fate map the mid-hindbrain border (Zinyk et al., 1998), neural-crest cell diversity 
(Epstein et al., 2000; Chai et al., 2000; Jiang et al., 2000), pancreatic islet cells (Herrera 
et al., 2000) and memory T cells (Jacob et al., 1999).   
To control not only the site of recombination but also the timing, an inducible 
form of Cre recombines has been developed.  The ligand-binding domain of a mutated 
estrogen receptor is fused to Cre recombinase (Cre-ERT).  This hybrid Cre is only 
activated by in the presence of tamoxifen but not endogenous steroids (Metzger et al., 
1995).  Similar hybrid Cre recombinases have been engineered using the ligand-binding 
domains of a mutated progesterone receptor and glucocorticoid receptor, which respond 
to RU486 and dexamethasone, respectively (Kellendonk et al., 1996; Brocard et al., 
1998).  The binding of the cognate ligand (e.g., tamoxifen) to the ligand-binding domains 
of a mutated steroid receptor (e.g., estrogen) allows translocation of the hybrid Cre (e.g., 
Cre-ERT recombinase) into the nucleus in which the hybrid Cre performs the 
recombination of its floxed DNA substrate, whereas the hybrid Cre stays in the cytoplasm 
in the absence of ligands.  It has been reported that the recombination efficiency was 
almost 100% in Cre-expressing cells after 3-days exposure of tamoxifen (Brocard et al., 
1997) and no detectable recombination was found in the absence of tamoxifen in the Cre-
ERT transgenic mice (Feil et al., 1996). However, some reports have suggested that 
incomplete and ligand-independent recombination have been identified in some of those 
ligand-activated Cre transgenic mice (Schwenk et al., 1998; Kellendonk et al., 1999).  It 
has been shown that transgenic mice expressing the Cre-ERT recombinase require 
relatively high doses of tamoxifen to induce recombination, which may cause undesired 
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side effects.  As a consequence, novel tamoxifen-inducible Cre recombinases have been 
sought out to increase sensitivity and efficiency of inducible recombination in mice.  Cre-
ERT2 has been proven to be approximately 10-fold more sensitive to tamoxifen than Cre-
ERT (Feil et al., 1997).  AT present, the Cre-ERT2 recombinase is suggested to be the best 
tool for the temporal-regulated somatic mutagenesis in mice.  
As reviewed above, gene targeting by homologous recombination is the essential 
genetic tool in science.  This technology has been further improved with Cre/lox 
recombination system, which allows researchers to inactivate gene of interest temporally 
and spatially at their will.  The reporter mouse lines have broadened up the utility of gene 
targeting.  Collectively, gene targeting with Cre/lox recombinase allows researchers to 
creatively study gene functions in vivo.   
 
Induced pluripotent stem cell (iPSC) technology 
Induced pluripotent stem cells (iPSCs) are genetically reprogrammed somatic 
cells re-acquiring embryonic stem cell-like properties by forced expression of defined 
factors that are important for the maintenance of stem cells.  Yamanaka and colleagues 
(2006) designed an elegant screen for “reprogramming” factors out of 24 stem cell-
related candidate genes that could activate the genetically engineered dormant drug 
resistance allele in the embryonic stem cell (ESC)-specific Fbxo15 locus.  Their screen 
identified the combination of 24 factors that activate Fbxo15 and generate the drug-
resistant colonies with distinctive ESC morphology when those 24 factors were expressed 
from retroviral vector in mouse embryonic fibroblasts (Takahashi & Yamanaka, 2006).  
Multiple rounds of screenings eventually identified the minimal set of four genes, Oct4, 
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Sox2, Klf4 and c-Myc that are required for the reprogramming.  Those drug-resistant 
(Fbxo15 expressing) ESC-like colonies are named as induced pluripotent stem cells 
(iPSCs).  Those iPSCs further complied with major criteria of pluripotency, such as 
expression of pluripotent stem cell markers (SSEA-1, and Nanog), teratoma formation 
upon the subcutaneous injection into immunocompromised mice, and contribution to 
different tissues during embryogenesis upon blastocyst injection (Hanna et al., 2010; 
Stadtfeld & Hochedlinger, 2010; Jaenisch & Young, 2008).   However, those iPSCs 
failed to generate chimeras or contribute to the germline because those iPSCs had 
insufficient levels of several crucial pluripotent genes in comparison with ESCs, and 
show only partial demethylation of stem cell regulator such as Oct4 (Takahashi & 
Yamanaka, 2006).  Following the success, Yamanaka and other laboratories improved the 
selection strategy by utilizing the essential gene loci including Nanog and Oct4 instead of 
Fbxo15, and successfully reproduced the Yamanaka’s initial findings.  In fact, iPSCs 
selected by selection of Nanog or Oct4 reactivation showed closer molecular and 
functional resemblance to ESCs (Maherali et al., 2007; Okita, et al., 2007; Werning et al., 
2007).    
Forced expression of four “Yamanaka” factors has successfully generated iPSCs 
from different species including humans, mice, rats, pig, and rhesus monkeys, which 
indicates that essential aspects of the transcriptional system regulating pluripotency 
remains conserved during evolution (Takahashi & Yamanaka, 2006; Takahashi et al., 
2007; Liao et al., 2009; Esteban et al., 2009; Liu et al., 2008).  Also, the Yamanka factors 
have been applied to generate iPSCs in a vareity of somatic cell types such as fibroblasts 
(Takahashi & Yamanaka, 2006), keratinocytes (Maherali et al., 2008), neural cells 
	   13	  
(Eminli et al., 2008), and melanocytes (Utikal et al., 2009), as well as genetically labeled 
pancreatic β cells (Stadtfeld et al., 2008a) and terminally differentiated lymphocytes 
(Hanna et al., 2008: Eminli, et al., 2009), which further suggests that conservation of 
transcriptional network of pluripotency.     
iPSC technology shows great potentials to be translated into clinical applications 
such patient-specific cell transplantation therapy.  To translate this technology into 
clinical applications, safe and efficient factor delivery methods must be engineered.  
Constitutively active retro- or lentiviral vectors are used to introduce Yamanaka factors 
into somatic cells. Both retro- and lentiviral vectors stably integrate its transgenes into the 
host genome upon the infection.  The retroviral delivery of Yamanaka factors often 
generates incomplete or partially reprogrammed cells lines that continuously depend on 
exogenous Yamanaka factor expression and fail to activate the corresponding 
endogenous factors because the retroviruses are typically shut down toward the end of the 
reprogramming process as a result of the activation of DNA and histone  
methyltransferases (Takahashi & Yamanaka, 2006).  Moreover, reactivation of the 
integrated retroviral transgenes in iPSC-derived somatic cells can disrupt the 
developmental potentials and often result in the formation of tumors in chimeric animals 
(Okita, et al., 2007).  As a delivery system, lentiviral vectors have advantage over 
retroviral vectors.   Lentivirus can infect different somatic cell types more effectively 
than retrovirus.  Also, lentiviral vectors can carry and express all four reprogramming 
factors as polycistronic cassette, thus increasing reprogramming efficiency.  Furthermore, 
the lentivirus can produce iPSCs more effectively than the retrovirus because the 
lentiviruses are less efficiently silenced than retroviruses in the infected host cells.  
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However, at the same time this can cause a differentiation block once the host cells gain 
pluripotency (Sommer et al., 2009).  To overcome a differentiation block in pluripotent 
cells, constitutively active lentiviral vectors have been further evolved into inducible 
lentiviral vectors.  The use of inducible lentiviral vectors, whose expression can be 
regulated by doxycycline treatments, significantly decreases the chance of continuous 
expression of exogenous Yamanaka factors.  The use of inducible lentiviral vectors also 
guarantee truly reprogrammed iPSCs because incomplete or partial reprogrammed iPSCS 
cease the proliferation upon doxycycline withdrawal (Sommer et al., 2009). 
As stated above, the viral delivery (either retro- or lentivirus) of Yamanaka 
factors poses potentially harmful effects such as the viral reactivation of transgenes and 
the insertion mutagenesis.  To circumvent the possible damaging effects, nonviral or 
integration-free delivery systems have been sought out. Specifically, it is specifically 
crucial that iPSC technology is applied to clinical settings.  Stadtfeld and colleagues 
(2008b) demonstrated iPSC generation of adult mouse hepatocytes by using 
nonintegrating adenoviral vectors.  Okita and colleagues (2008) also showed that mouse 
embryonic fibroblasts were reprogrammed by transfection of DNA plasmids.  
Furthermore, human fibroblasts have been reprogrammed into human iPSCs by using 
adenoviral vectors (Zhou and Freed, 2009), Sendai virus (Fusaki et al., 2009) as well as 
polycistronic mini circle vectors (Jia et al., 2010) and self-replicating selectable episomes 
(Yu et al., 2009).  These reports strongly support that transient expression of four 
Yamanaka factors is sufficient to induce pluripotentcy in somatic cells.  Those reports 
also validate the absence of common integration sites in iPSCs generated with 
retroviruses or lentiviruses, which suggests that insertion mutagenesis at best plays a 
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supportive role during iPSC generation.  A significant drawback of nonintegrating 
delivery system is substantially low reprogramming efficiency.  Reprogramming 
efficiency with the nonintegrating vectors is several folds lower (~0.001%) than that with 
integrating vectors (0.1% ~ 1%) (Stadtfeld & Hochedlinger, 2010).   
It appears that nonintegrating vectors cannot sustain the expression of four 
Yamanaka factors for an adequate amount of time to achieve complete epigenetic 
remodeling.  To overcome the low reprogramming efficiency of nonintegrating vectors, 
excisable integration-dependent gene delivery vectors have been explored.  The 
integrating gene delivery vectors, such as lentiviruses, are devised with incorporated loxP 
sites that can be excised from the host genome upon transient expression of Cre-
recombinase.  This gene delivery strategy can still generate iPSC effectively from 
different cell types if polycistronic vectors are utilized (Sommer et al., 2010).  Inevitably, 
this strategy leaves short vector sequences, such as loxP site in the host genome after 
excision.  It still remains to be seen if these short vector sequences have an effect on 
cellular function of the host.  Furthermore, integration-free iPSCs can be generated with 
piggyBac DNA transposons, mobile genetic elements that can be inserted and removed 
from the host genome by transient expression of transposase.  PiggyBac transposons are 
an ideal gene delivery system because this vector leaves no vector sequence behind upon 
the excision.  But integration sites in iPSCs are still needed to be characterized before and 
after transposons are removed (Kaji et al., 2009; Woltjen, et al., 2009).  It also remains 
unknown if the transposase expression can cause nonspecific genomic modification in 
iPSCs.   
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iPSCs have been successfully generated without the use of viral or plasmid 
vectors.  Zhou and colleagues (2009) have reported that human and mouse fibroblasts 
have been successfully reprogrammed by application of purified recombinant proteins of 
four Yamanaka factors.  In addition, successful reprogramming has been accomplished 
by delivery of four reprogramming factors as whole-cell extracts isolated from either 
ESCs (Cho et al., 2010) or genetically engineered HEK293 cells (Kim et al, 2009).  The 
delivery of four reprograming factors as purified proteins appears to be the ultimate way 
to achieve transgene-free iPSC; however reprogramming efficiency of four recombinant 
proteins is exceptionally low.  The recombinant proteins of four reprogramming factors 
also required the aid of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) for 
its successful iPSC generation (Zhou et al., 2009).  Recently, modified RAN- and 
miRNA-based reprogramming approaches, which may be more effective and safer, have 
successfully achieved iPSC generation from human and mouse somatic cells (Warren et 
al., 2010; Anokye-Danso et al., 2011). 
Whether using integrating or nonintegrating methods, overall reprogramming 
efficiency of iPSC generation is not as high as one can desire.  To improve the overall 
low efficiency of this technology, chemical compounds that can facilitate reprogramming 
processes have been researched.  Several laboratories have identified numerous 
molecules that can substantially increase reprogramming efficiency in the presence of the 
four reprogramming factors (refer to Li and Ding, 2010; Feng et al., 2010 for review).  
Some of those reprogramming-capable molecules can take the place of individual 
reprogramming factors, Oct4, Sox2, Klf4, and c-Myc, which suggests that those 
reprogramming-capable molecules can be used solely to derive iPSC formation.  
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However, there is often a dramatic decrease in the number of iPSC colonies when those 
reprogramming factors are replaced by the small molecules, which indicates that no 
single chemical compound is able to fully take the place of a transcription factor as its 
function.  It should be noted that those reprogramming-capable compounds are shown to 
be powerful modulators of DNA and chromatin modifications.  Thus, chemical 
reprogramming may potentially introduce genetic or epigenetic abnormalities into iPSCs.   
Reprogramming inefficiency (0.01% ~ 0.1%) and slow kinetics (~2 weeks) have 
been the major stumbling blocks of iPSC technology, which suggests that there are chief 
molecular events that may act as “roadblocks” during the reprogramming processes 
(Stadtfeld et al., 2008c; Brambrink et al., 2008).  Molecular and cellular mechanisms 
underlying iPSC generation must be elucidated for potential use of this technology in 
clinical settings in future.  Two models have been put forward to explain the low 
efficiency and slow kinetics of reprogramming.  The “elite” model describes only a few 
cells in a somatic cell culture are amenable to reprogramming and thus the efficiency of 
reprogramming is significantly low.  The most palpable candidate cells are somatic stem 
cells or progenitor cells in adult tissues and explanted cells populations since they are 
scarce and developmentally closer to pluripotent.  On contrary, the “stochastic” model 
states that all somatic cells are equally susceptible to reprogramming yet have to undergo 
a series of stochastic epigenetic events to gain pluripotentcy.  Ultimately only a few cells 
may be able to overcome the epigenetic barriers or roadblocks to acquire pluripotency; 
therefore, the reprogramming efficiency is low.  Both elite and stochastic model are 
supported by experimental evidence.  For instance, iPSCs formation can be achieved 
from the defined somatic cells types such as pancreatic β cells (Stadtfeld et al., 2008a) 
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and fully differentiated B and T lymphocytes (Hanna et al., 2008; Eminli et al., 2009).  
Furthermore, when clonal populations of early β cells monocytes expressing 
reprogramming factors were followed, a vast majority of cell clones eventually generated 
the daughter cells that formed iPSCs between several weeks to months (Hanna et al., 
2009a).  It suggests that rare cells in a homogenous cell population can go through 
stochastic changes that promote their conversion into pluripotent state with multiple 
rounds of cell proliferation (Hanna et al., 2009a).  On the other hand, it has been 
demonstrated that clonal populations of hematopoietic stem cells and progenitor cells 
become iPSCs more efficiently (10% ~ 40%) and faster than mature lymphocytes and 
myeloid cells (0.01% ~ 1%) in spite of the proliferative state of cells at the time of factor 
expression (Eminli et al., 2009).  This suggests that the differentiation status of cells may 
be an influential factor for iPSC generation.  Intuitively thinking, since adult progenitors 
and stem cells are developmentally immature, they have to go through fewer stochastic 
epigenetic events to be reprogrammed than fully differentiated cells, which can explain 
the faster and more efficient iPSC generation from adult progenitors and stem cells.  In 
fact, those developmentally immature cells up-regulated pluripotency markers faster than 
terminally differentiated cells during the reprogramming process (Eminli et al., 2009).  
Thus, a true mechanism of reprogramming efficiency and kinetics may be explained by a 
combination of those two models.                     
The reprogramming process appears to be a well-ordered sequence of events.  
This organized sequence of events begins with down-regulation of somatic-specific genes 
and mesenchymal-to-epithelial transition (MET)-like morphological changes, which is a 
crucial early phase of reprogramming as activation of Tgf β signaling, inhibition of BMP 
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signaling or depletion of MET gene such as E-Cadherin cancel reprogramming 
(Stadtfeld, et al., 2008c; Li et al., 2010; Mikkelsen et al., 2008; Samavarchi-Tehrani, et 
al., 2010).  Following these events, early pluripotentcy markers SSEA-1, alkaline 
phosphatase and Fbxo15 become expressed (Stadtfeld et al., 2008c; Brambrink et al., 
2008).  Cells become independent from exogenous reprogramming factors as true 
pluripotency genes such as Nanog or Oct4 are activated (Maherali et al., 2007; Stadtfeld 
et al., 2008a).  Distinct differences in telomere length, global transcriptional and DNA 
methylation patterns have been identified between early- and late-passage iPSCs, which 
suggests that the acquisition of pluripotency may not be finished upon the transition from 
exogenous to endogenous expression of four reprogramming factors, and may need 
several rounds of cell divisions (Marion et al., 2009; Chin et al., 2009; Polo et al., 2010).  
Genome-wide analyses of histone methylation marks (H3K9me2, H3K4me3, 
H3K27m33) and DNA methylation showed significant differences between fibroblasts, 
partial-reprogrammed iPSCs and fully reprogrammed iPSCs and they are re-set to ES 
cell-like patterns (Maherali et al., 2007; Mikkelson et al., 2008; Chin et al., 2009; Doi et 
al., 2009; Sridharan et al., 2009; Hawkins et al., 2010).   Additionally, it has been 
demonstrated that asymmetric cysteine methylation, which is extensively observed in ES-
cells, is restored in fully reprogrammed iPSCs (Lister et al., 2009).  The evidence above 
indicates that the transition to pluripotent state is associated with a major re-setting 
chromatin landscape.   
It has been shown that down-regulation of somatic-specific markers and 
activation of embryonic markers are observed in only fraction of fibroblasts expressing 
reprogramming factors (Wernig et al., 208; Stadtfeld et al., 2008a).  This suggests that a 
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vast majority of cells are refractory to reprogramming or become refractory as a result of 
ectopic expression of reprogramming factors.  Reprogramming intermediates selected 
based on the combination of pluripotency markers described above have an increased 
chance of generating iPSC colonies, which suggests that those reprogramming 
intermediates have indeed passed some transcriptional and epigenetic barriers that 
normally block the induction of pluripotency (Stadtfeld et al., 2008c).  Taken together, 
the arrest of somatic program and the consequential activation of endogenous pluripotent 
genes may be a roadblock during iPSC generation.   
Among key endogenous pluripotent regulators, activation of endogenous Nanog 
locus by reprogramming factors may be the most critical since it co-binds numerous 
targets of Oct4, Sox2, and Klf4 in ES cells as well as biochemically interacts with Oct4 
and other transcription factors in ES cells (Wang et al., 2006).  Since Nanog is up-
regulated only late during reprogramming, it has been speculated that Nanog may be 
limiting for efficient transition of somatic cells to iPSCs (Hanna et al., 2010).  In 
agreement with this theory, Nanog positively influences reprogramming by cell fusion 
(Silva et al., 2006).  Likewise, Tgf β inhibition, which is a critical process for transition to 
the pluripotent state, may be regulated through up-regulation of Nanog (Ichida et al., 
2009).  Most essentially, it has been shown that Nanog is absolutely required for 
complete induction of pluripotency only during the final stages of the reprogramming 
process (Silva et al., 2009).  Finally, overexpression of Nanog as well as other 
pluripotency transcription factors such as Sall4 and Tbx3 has been shown to boost 
reprogramming efficiency (Hanna et al., 2009a; Tsubooka et al., 2009; Wang et al., 2006; 
Liang et al., 2008; Yang et al., 2008).   
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It has been suggested that re-establishment of ES cell-like chromatin state is vital 
for the reprogramming process.  The promoters of pluripotency genes such as Nanog and 
Oct4 are known to be silenced securely by DNA methylation in somatic cells (Gidekel & 
Bergman 2002).  The promoter DNA methylation profiles of Nanog and Oct4 have been 
specifically examined between mouse embryonic fibroblasts (MEFs), reprogramming 
intermediates, iPSCs and ESCs.  The promoters of those pluripotency genes are 
hypermethylated in MEFs and reprogramming intermediates whereas those promoters are 
unmethylated in iPSCs and ESCs (Maherali et al., 2007; Mikkelsen et al., 2008).  In 
agreement with the idea that DNA methylation interferes with the binding of transcription 
factors and subsequent gene activation during reprogramming, the reprogramming 
efficiency is enhanced with the addition of the DNA demethylating drug, 5-azacytidine as 
well as depletion of maintenance methyl transferase Dnmt1(Mikkelsen et al., 2008).  It is 
not clear how these epigenetic roadblocks are surpassed in the process of iPSC formation.  
However, it has been speculated that passive or active mechanisms may be in place to 
reduce DNA methylation in the promoters of pluripotency genes (Hockedlinger & Plath 
2009).  Collectively, this evidence indicates that chromatin states may also be roadblocks 
in the reprogramming process. 
ES cells possess a self-renewal capability, which grants them immortality.  
Fibroblasts and other somatic cell types are limited in their proliferative potential and 
undergo apoptosis, growth arrest, and stress-induced senescence in culture.  Therefore, 
the acquisition of cellular immortality could be another biological barrier to the 
reprogramming process.  In fact, serial passages of fibroblasts are highly correlated with 
a decrease in reprogramming efficiency (Utikal et al., 2009).  It has been reported that 
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increased proliferation is observed at an early phase of fibroblast reprogramming 
(Mikkelsen et al., 2008).  Up-regulation of genes driving cell cycle progression also 
seems to be an early event during fibroblast reprogramming (Mikkelsen et al., 2008).    
However, as stated earlier, cells at the intermediate stages of reprogramming have shown 
the dependence to exogenous factor expression for continuous growth, which indicates 
that the acquisition of immortality takes place late during the reprogramming process.  In 
agreement with the hypothesis that acquisition of cellular senescence is a roadblock 
during fibroblast reprogramming, ectopic expression of four reprogramming factors in 
p53 or lnk4a/arf deficient immortalized fibroblasts enhanced the reprogramming 
efficiency and kinetics (Banito et al., 2009; Hong et al., 2009; Kawamura et al., 2009; Li 
et al., 2009; Marion et al., 2009; Utikal et al., 2009).   
Besides the role in facilitating the reprogramming described above, p53 loss may 
also promote reprogramming efficiency by blocking DAN-damaged induced apoptosis 
(Marion et al., 2009).  Interestingly, however, p53 loss can evoke different responses in 
cells expressing four reprogramming factors.  In fibroblasts, loss of p53 contributed to 
reprogramming by inhibiting senescence and cell death whereas in blood cells with 
ectopic expression of four factors, p53 loss contributed to reprogramming by accelerating 
cell cycle progression (Hanna et al., 2009b).  Together, this evidence indicates 
senescence and apoptosis as potential roadblocks to the reprogramming process.   
iPSC technology holds enormous potential to translate into therapeutic tools.  
Organ transplantation among unrelated individuals involves complications such as the 
limited availability of matched organs and life-long treatments with immunosuppressive 
drugs that may cause serious side effects.  These problems can be overcome since iPSCs 
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can be differentiated into the desired cell types that are already genetically matched with 
the patients.  The feasibility of cell therapy with iPSCs to genetic disorders has been 
tested in mice.  It has been demonstrated that iPSCs are capable of rescuing the defects in 
a mouse model of sickle cell anemia (Hanna et al., 2007).  Sickle cell anemia is caused by 
the single point mutation in the hemoglobin gene, which results in the dysfunction of red 
blood cells. iPSCs were generated from skin cells isolated from the mouse model, which 
recapitulated the disease phenotypes in humans (Hanna et al., 2007).  Afterwards, the 
disease-causing mutation was corrected in iPSC by gene targeting, and the repaired 
iPSCs were further differentiated into the blood-forming progenitors.  Those “cured” 
progenitors were later transplanted into anemic mice in which those progenitors 
generated normal red blood cells and cured the disease.  This approach could be 
applicable to any human disease for which the disease-causing mutation is known and 
could be treated by cell transplantation.  In fact, the phenotypes of the hemophilia A in 
mice were corrected by transplantation of heterologous, iPSC-derived endothelial 
progenitors (Xu et al., 2009).          
The study and treatment of degenerative disorders such as type I diabetes, 
Alzheimer’s disease and Parkinson’s disease also are difficult, because of the availability 
of the perturbed tissues and the inability to culture those affected cell types for an 
extended period of time.  iPSCs may be used to generate iPSCs from skin cells of the 
affected patients and later differentiate them in vitro into the perturbed cell types.  Thus, 
the researchers can re-establish the disease in Petri dishes.  This “disease-modeling” 
approach is useful because iPSC can re-create and study the actual cell types that are 
compromised and lost in the patients (Saha & Jaenisch 2009; Abeliovich & Doege 2009; 
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Gubaseeli et al., 2010; Koch et al., 2009; Stadtfeld & Hochedlinger 2010).  Furthermore, 
iPSCs can be an unlimited source for any desired specialized cells because iPSCs grow 
indefinitely in culture.  In the long run, this approach can be used as an in vitro screen 
system and can identify a novel compound to treat the disease including amyotrophic 
lateral sclerosis (ALS) and spinal muscular atrophy (SMA) (Dimos et al., 2008; Ebert et 
al., 2009).  This approach also allows researchers to re-cerate and capture the very early 
stage of degenerative diseases since iPSCs have to undergo the same differentiation 
process in culture as the patients experience during the disease progression.  This is 
especially critical because cellular specimens are generally isolated from the patients who 
have progressed further to advanced stages of diseases at the time of diagnosis; thus 
major events of diseases have taken place and been missed.  Ultimately, this technology 
may provide valuable insights into the timing and causes of degenerative disorders. 
As reviewed above, iPSC technology has provided a unique opportunity to study 
detailed mechanism of cellular reprogramming.  Indeed, since the invention of this 
technology, researchers have gained extensive knowledge of cellular reprogramming and 
stem cell behaviors.  Although there are still key improvements to be made such as the 
invention of safe and efficient gene delivery methods (i.e., integration-free iPSCs with 
intact epigenetic integrity), this technology holds great promise to be translated into 
therapeutic tools in the future.        
 
DNA transposon system 
Transposable elements or transposons are distinct mobile elements capable of 
moving around and replicating within the genome of an organism.  Transposons were 
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first identified by Barbara McClintock in the maze genome, and have been identified 
basically in all living organisms since the discovery (Lewin 2001).  For instance, 
approximately 45% of the human genome is made out of the transposon-derived 
elements.  Nonetheless, a vast majority of the transposons were inactive millions of years 
ago (International Human Genome Sequencing Consortium 2001).  Transposons could be 
best described as molecular parasites that propagate themselves by using the hosts’ 
resource.  Transposons are noninfectious unlike viruses.  The parasitic activities are 
limited within cells, which have forced transposons to develop harmless strategies toward 
the host in order to coexist and survive with the host (Hartl et al., 1997).  In spite of their 
parasitic nature, it has been suggested that transposons might be a strong force in gene 
evolution (Izsvak & Ivics 2003).  For instance, approximately 50 human genes are 
originated from transposable elements.  Among those there are genes that are responsible 
for recombination of immunoglobulin gene in all vertebrates (Izsvak & Ivics 2003).   
Transposons are categorized into two main classes: retrotransposons and DNA 
transposons.  Retrotransposons are mobile elements transposing through RNA 
intermediates such as long interspersed elements (LINEs), short interspersed elements 
(SINEs), and long terminal repeats (LTR) retrotransposons.  Retrotransposons utilize a 
“copy-and paste” mechanism of transposition.  The donor elements are not mobile, but 
reverse transcription replicates the donor elements (copy), which insert (paste) elsewhere 
in the genome.   DNA transposons are mobile elements that can relocate directly as DNA 
within the genome by a “cut-and-paste” mechanism, in which the element itself is excised 
from the donor site and is reinserted elsewhere in the genome (Mates et al., 2007; Izsvak 
& Ivics 2003; Carlson & Largaespada, 2005; Copeland & Jenkins 2010).       
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DNA transposons show great potential as powerful genetic tools because they are 
safe nonviral vectors that can transfer a define DNA segment from one location to 
another (Mates et al., 2007; Izsvak & Ivics 2003; Carlson & Largaespada, 2005; 
Copeland & Jenkins 2010).  In invertebrates such as flies and worms, endogenous 
elements, such as P-element and Tc1 element for Drosophila and Caenorhabditis elegans 
respectively, have been developed as tools for insertional mutagenesis and germline 
transgenesis (Cooley et al., 1988; Plasterk 1996).  Unfortunately, no active endogenous 
element was available in vertebrates until recently (Mates et al., 2007; Izsvak & Ivics 
2003; Carlson & Largaespada, 2005; Copeland & Jenkins 2010).  A Tc1-like active DNA 
transposon, Sleeping Beauty was reconstructed from salmanoid fish and has been shown 
to be highly active in human and mouse cells.  Sleeping Beauty has been tested for germ 
line mutagenesis, but it has not been as effective as it is in vitro (Mates et al., 2007; 
Izsvak & Ivics 2003; Carlson & Largaespada, 2005; Copeland & Jenkins 2010).  
Following the discovery of Sleeping Beauty, a new Tc1-like active DNA transposon, 
piggyBac has been isolated from the cabbage looper moth, Trichoplusia ni.  piggyBac 
transposons have been shown to be highly active in mouse cells and have demonstrated a 
significantly high efficiency for germ-line mutagenesis in mice (Handler 2002; Mates et 
al., 2007; Izsvak & Ivics 2003; Carlson & Largaespada, 2005; Copeland & Jenkins 
2010).   
Sleeping Beauty transposon is the best-characterized DNA transposon among the 
known Tc1-like DNA transposons.  The structure and transpositional mechanism of 
Sleeping Beauty have been well-studied.  I use Sleeping Beauty as an example to describe 
the structure and mechanism of DNA transposition and discuss critical differences in the 
	   27	  
structure and transpositional mechanism between piggyBac and Sleeping Beauty.  DNA 
transposons of Sleeping Beauty and piggyBac have a simple gene structure (Figure 1-3).  
In nature, DNA transposons are made of a single gene encoding the transposase 
polypeptide, the emzymatic factor of transposition, which is flanked by terminal inverted 
repeats (IRs) that are binding sites for the transposase.  In the laboratory, the transposase 
gene can be physically separated from the IRs, and replaced with any DNA sequence 
desired.  Transposases can mobilize the transposons in trans as long as the IRs are 
present.   Transposases can be supplied as a form of another DNA molecule, fused DNA 
with your cargo, mRNA or protein (Mates et al., 2007; Izsvak & Ivics 2003; Carlson & 
Largaespada, 2005; Copeland & Jenkins 2010).   
The terminal inversed repeats (IRs) of both DNA transposons contain two 
direction repeats (DRs) (Figure 1-3).  The distinctive organization of terminal inverted 
repeats (IRs) is known as IR/DR, which is evolutionarily conserved among the Tc1-like 
transposable element and is a strict requirement for the transposition.  Sleeping Beauty 
transposons have short 15-20-bp imperfect DRs that contain two transposase binding 
sites.  piggyBac transposons have 13-bp perfect inverted terminal repeats and 19-bp 
subterminal repeats located 31-bp from the 5’ IR and 3-bp from 3’ IR.  All four binding 
sites are required for the transposition.  Specific binding to DRs of Sleeping Beauty 
transposase is mediated by an N-terminal, pair-like DNA-binding domain, which consists 
of PAI and RED subdomain.  The RED subdomain partially overlaps with a nuclear 
localization signal that is flanked by phosphorylation target sites of casein.  The 
phosphorylation of those sites serves as a checkpoint for the regulation of transposition.  
The nuclear localization signal gives the transposases easy entry to the host by taking   
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Figure 1- 3. Structure of Sleeping Beauty and PiggyBac transposons (Top Panel).  
The functional domains of Sleeping Beauty transposable element (Middle Panel).  
The “cut-and-pasts” transposition mechanism of Sleeping Beauty transposon and a 
hypothesized functional role of DNA-binding high-mobility group B1 protein 
(HMGB1) in Sleeping Beauty synaptic complex formation (Bottom 
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Figure 1-3 Cont.  
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advantage of the host’s own receptor-mediated transport machinery.  An AT-hook motif, 
which is made of two HTH motifs connected by a signature GRPR-like motif, has been 
found in Sleeping Beauty transposase as a functional domain responsible for DNA minor 
groove interaction.  The catalytic domain of Sleeping Beauty transposase, which is 
responsible for DNA breakage and joining reactions, is characterized by conserved amino 
acid motif, the DDE motif (Figure 1-3).  The DDE motif has been found in a large group 
of recombinases such as bacterial IS element transposases, retrotransposon/retroviral 
integrases, and RAG1 immunoglobin gene recombinase.  It has also been suggested that 
the catalytic domain of DDE recombinases is involved in mediating interaction with the 
target DNA (Mates et al., 2007; Izsvak & Ivics 2003; Carlson & Largaespada, 2005; 
Copeland & Jenkins 2010).   
The transposition process can be divided into four major phases: 1) transposase 
binding to the specific binding sites in the transposon DRs; 2) synaptic complex 
formation in which the two ends of the transposable elements are paired and held together 
by the transposase subunits; 3) excision from the donor site; 4) reinsertion at a new target 
site (Figure 1-3).   Importantly, multiple layers of the regulatory molecular “checkpoints” 
are installed in each phase of the transposition process for Sleeping Beauty (or piggyBac) 
to mobilize its own transposable elements (Mates et al., 2007; Izsvak & Ivics 2003; 
Carlson & Largaespada, 2005; Copeland & Jenkins 2010).  
One checkpoint is specificity of DNA binding by the Sleeping Beauty transposase.   
The PAI subdomain of Sleeping Beauty transposase recognizes the binding site of 
3’DR/IR in base-specific manner whereas the RED subdomain interacts with the specific 
sequence of 5’DR/IR.   Additionally, the PAI subdomain interacts with the HDR motif in 
	   31	  
the left IR of Sleeping Beauty transposable element, and facilitates protein-protein 
interaction between other transposase subunits.  As a consequence, the PAI domain has 
three critical regulatory roles in the first phase of transposition, such as interactions with 
both the DRs and the HDR motif, and transposase oligomerization.  The zebra fish Tdr1 
element is highly related to Sleeping Beauty transposons; however, the Sleeping Beauty 
transposase cannot mobilize the Tdr1 transposable element.  It has been demonstrated 
that major differences lies in the 5’half of the DRs between the Tdr1 and Sleeping Beauty 
transposons.  As the mediator of 5’binding specificity, the RED subdomain recognizes 
the difference in the 5’DRs from those of other transposable elements and prevents 
mobilization of the closely related transposable elements (Mates et al., 2007; Izsvak & 
Ivics 2003; Carlson & Largaespada, 2005; Copeland & Jenkins 2010).    
The other checkpoint is the orders of Sleeping Beauty synaptic complex formation 
that are orchestrated by the high mobility protein HMGB1.  The synaptic complex 
assembly is the process where the two ends of the Sleeping Beauty transposable element 
are held together by the Sleeping Beauty transposases (Figure 1-3).  HMGB1 is non-
histone nuclear protein that is associated with the eukaryotic chromatin and is capable of 
bending DNA.  It has been shown that HMGB1 is required for effective Sleeping Beauty 
transposition in mammalian cells.  Transposition efficiency of Sleeping Beauty 
transposons showed significant reduction in the cells from HMGB1-mutant mice.  
Furthermore, overexpression of HMGB1 promotes significant transposition efficiency in 
the normal mouse cells, which suggests that HMGB1 is a limiting factor of transposition.  
Additionally, HMGB1 was found to bind Sleeping Beauty transposase in vivo and 
assemble a ternary complex with the transposase and transposon DNA, which indicated 
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that the transposase might actively recruit HMGB1 to transposon DNA through protein-
protein interaction.  It has been reported that Sleeping Beauty transposase preferentially 
interacts with the inner DRs within the transposon inverted repeats.  HMGB1 was shown 
to facilitate transposase binding more toward the inner DRs than the outer DRs.   This 
evidence points out that HMGB1 ensures the orderly assembly of the catalytically ready 
synaptic complex during the early phase step of transposition.  In fact, Sleeping Beauty 
transposase cannot achieve the transposition when the inner binding sites are swapped 
with the outer binding sites.  Combined together, the ordered synaptic formation appears 
to regulate the cleavage of outer sites of DNA transposons, which occurs only when all 
the prerequisites have been met (Mates et al., 2007; Izsvak & Ivics 2003; Carlson & 
Largaespada, 2005; Copeland & Jenkins 2010).            
During the excision phase, the cuts at the ends of the Sleeping Beauty transposon 
are staggered inward by three nucleotides, which generate 3’ overhangs and leave the 
nucleotides of the terminal inverted repeats (IRs) at the donor site.  This creates the 3-bp 
transposon footprints upon the repair of double-strand DNA breaks of the broken DNA 
ends.  In contrast, piggyBac transposase leaves no footprint during the excision of the 
piggyBac transposon from the donor site. Sleeping Beauty transposons integrate relatively 
randomly; however, Sleeping Beauty transposons do not utilize all available sites in the 
genome with equal frequencies (Handler 2002; Mates et al., 2007; Izsvak & Ivics 2003; 
Carlson & Largaespada, 2005; Copeland & Jenkins 2010).  Vigdal and colleagues (2002) 
performed in vitro transposition assay in human Hela cells to analyze insertion profile of 
Sleeping Beauty transposons.   They showed that no clear preference was detected for any 
chromosome or for specific subchromosomal regions although some chromosomes were 
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hit more often than others.  The results indicated that most chromosomes could be good 
targets for transposition.  Vigdal and colleagues (2002) also found 35% of transposition 
events took place in transcribed regions.  It has been suggested that approximately one 
third of the human genome is transcribed; therefore, this frequency of gene transcription 
indicates no preference for or against insertion into genes (International Human Genome 
Sequencing Consortium 2001).  Furthermore, Sleeping Beauty transposon preferentially 
inserts at TA dinucleotides.  Further analysis revealed that Slepping Beauty preferred a 
short palindromic AT-repeat: ATATATAT, where the central underlined TA is the 
insertion site.  In contrast, piggyBac transposons preferentially integreate at 
tetranucleotide TTAA sites (Handler 2002; Mates et al., 2007; Izsvak & Ivics 2003; 
Carlson & Largaespada, 2005; Copeland & Jenkins 2010).  
Ding and colleagues (2005) first demonstrated that the piggyBac transposon was 
able to effectively perform insertional mutagenesis in the mammalian cells and in mice 
(Ding et al., 2005).  Following the success of Ding and colleagues, several laboratories 
have made further improvement of the piggyBac transposon system as the effective 
mutagenesis tool (Wu et al., 2007, Cadinanos and Bradley 2007; Roland et al., 2010; Kaji 
et al., 2010; Woltjen et al., 2010; Yusa et al., 2009).  For instance, Bradley and colleagues 
have identified the coding sequence of piggyBac transposase, which optimize the 
transposition efficiency.  Bradley and colleagues engineered inducible piggyBac 
transposase by fusing the optimized piggyBac transposase with the modified estrogen 
ligand-binding domain (ERT2), and showed the efficiency of this inducible system in 
mice (Cadinanos and Bradley 2007).  Because of the high integration efficiency of 
piggyBac transposons, the piggyBac transposon system has been used as the effective 
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transgene deliver system of iPSC formation (Kaji et al., 2010; Woltjen et al., 2010).  
Since Bradley and collegaues have demonstrated that the integrated piggyBac 
transposons could be excised cleanly out of the host genome (Yusa et al., 2009), the 
piggyBac transposon system holds great promise to be further improved as a safer and 
effective method to generate patient-specific iPSCs.  Collectively, DNA transposon 
systems such as piggybac transposons are a powerful genetic tool to study gene functions 
both in vitro and vivo.	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CHARACTERIZATION OF CANINE QUANTITATIVE TRAIT 
LOCUS (QTL) IN MOUSE BY CANINE iPS CELLS AND  





The dog (Canis familiaris) has been not only the best friend of the humans but 
also the most valuable work force for long time since its first domestication, which is 
estimated to be between 15,000 and 150,000 years ago (Ostrander et al, 2005; Wayne & 
Ostrander, 2005: Ostrander & Wayne; 2005; Sutter & Ostrander, 2004).  Over centuries 
the dog has served us shepherd, guide, hunter, protector and a model organism for 
medical research.  In order to meet needs and demands in our human lives, we desire to 
create dogs with particular physical and behavioral traits or special skills (Ostrander et al, 
2005; Wayne & Ostrander, 2005; Ostrander & Wayne, 2005; Sutter & Ostrander, 2004).  
For centuries, we have been practicing selective breeding to create a perfect breed 
meeting a certain phenotypic standard (e.g., temperament and sharpness) (Ostrander et 
al., 2005; Wayne & Ostrander, 2005; Ostrander & Wayne, 2005; Sutter & Ostrander, 
2004).  The chief purpose of the selective breeding is to create dogs that are physically 
“fit” to specific tasks.  For instance, the long-bodied dachshunds are made for hunting 
badgers underground.  The heavy-coated komondors are developed to guard large herds 
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of animals on the open plains.  The web-footed newfoundlands are made to be natural 
and powerful swimmers (Ostrander et al, 2005; Wayne & Ostrander, 2005;Ostrander & 
Wayne; 2005; Sutter & Ostrander, 2004).  As a result, the selective breeding practice of 
dogs has created a broad variety of phenotypic traits with different heights, weights, bone 
structures and hair coats (Ostrander et al, 2005; Wayne & Ostrander, 2005; Ostrander & 
Wayne, 2005; Sutter & Ostrander, 2004).  In point of fact, the domestic dogs are known 
to be the most morphologically and diverse mammalian species on earth, and almost all 
combinations of physical traits have been generated and fixed within specific breeds, 
which makes domestic dogs an exceptional model for studying morphological variations 
in humans (Ostrander et al., 2005; Lark et al., 2006). 
Lark and his colleagues take advantage of the morphological diversity of the 
domestic dogs and examine the genetic basis for skeletal variation in Portuguese water 
dogs (Lark et al., 2006; Chase et al., 1999; Chase et al., 2002; Carrier et al., 2005).  
Among the pure breeds of domestic dogs, the Portuguese water dog is a breed that is 
allowed large variation in skeletal size by the American Kennel Club, which makes this 
breed an attractive breed to study skeletal variation.  Furthermore, this breed consists of a 
reasonable number of individuals (~10000) that were generated by a small founders 
population (33 dogs)(Ostrander et al., 2005; Lark et al., 2006).  Because of generous 
support from owners, phenotypic and genotypic materials, which are X-rays and blood 
samples respectively, are easily corrected.  The accuracy of the pedigree is tremendous so 
that individual dogs can be traced back to the founders (Lark et al., 2006; Chase et al., 
1999; Chase et al., 2002; Carrier et al., 2005).  Finally, their primary assessment, which is 
the measurements of 12 morphological parameters (e.g., height at shoulder, length of tail, 
  
47 
length of body, height at hock, distance between eyes) measured by 300 owners with tape 
measures, revealed that morphological phenotypes segregate.  Simulation based on these 
raw date could prove the evidence of sufficient heritability of different 
morphological/quantitative traits, which would lead to identification of the loci of those 
quantitative traits (Lark et al., 2006; Chase et al., 1999; Chase et al., 2002; Carrier et al., 
2005).    
Quantitative traits are also called complex traits because the traits are affected by 
multiple genetic and environmental factors.  Regions in the genome where it harbors 
multiple genes contributing to a complex trait are known as quantitative trait loci (QTLs) 
(Lark et al., 2006; Chase et al., 1999; Chase et al., 2002; Carrier et al., 2005).  
Quantitative traits such as metric traits, which are measurable on a continuous scale (e.g., 
height or weight), are distinguished from traits that look discrete such as round versus 
wrinkle pea seeds (Chase et al., 1999).  In studies of the Lark’s group, metrics of the 
canine skeleton obtained by direct measurement or from radiographs are used as the 
quantitative traits of interest (Lark et al., 2006; Chase et al., 1999; Chase et al., 2002; 
Carrier et al., 2005).  Principle component (PC) analysis was used to classify phenotypic 
variation into independent systems of correlated traits (Jackson, 1991; Hartl, 2001).  
Individual dogs have a value for every PC.  Thus, PCs are phenotypes that are subject to 
genetic analysis and QTLs can be identified that inform these phenotypes (Lark et al., 
2006; Chase et al., 1999; Chase et al., 2002; Carrier et al., 2005).  Although this analysis 
uses numerous skeletal metrics, which increases statistical power, the analysis focuses on 
the pattern of multiple metrics and will not capture independent variation of the metrics 
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of individual bones.  Therefore, it enables the researchers to detect QTLs with pleiotropic 
effects preferentially (Lark et al., 2006; Chase et al., 2002; Carrier et al., 2005).  
PC analyses in skeletal variations in Portuguese water dogs revealed that PCs 
individually promote both correlations within structures (e.g., within the skull or among 
the limb bones) and inverse correlations between structures (e.g., skull vs. limb bones).  
This finding is described as a trade-off that forms compromise between high production 
of power and energy-efficient speed (Lark et al., 2006; Chase et al., 2002; Carrier et al., 
2005).  For instance, a smaller head and large postcranial body is linked to speed, which 
is observed in the greyhound, and a large head and smaller postcranial body is associated 
with power, such as a pit bull.  This sharp variation is described by one principle 
component.  Furthermore, there is another PC characterizing independent component of 
sharp variation that influences metrics of length and width (Lark et al., 2006; Chase et al., 
2002; Carrier et al., 2005).  For instance, a long and thin limb bone is connected to speed 
(e.g., greyhounds), whereas a shorter and thicker limb bone is associated with power 
(e.g., pit bulls).  Using phenotypic data from the radiograph corrected and polymorphic 
molecular makers (Simple Sequence Repeats or SSR), the group has identified a QTL 
that regulates the principle component involving a trade-off between length and width of 
limb bones. This QTL is associated with the SSR marker FH3585 on the canine 
chromosome (CFA) 12 (Lark et al., 2006; Chase et al., 1999; Chase et al., 2002; Carrier 
et al., 2005).  At this locus, specific haplotypes control both length and width of limb 
bones.  D haplotye and E haplotype regulates both length and width of radius.  D 
haplotype gives rise to a wider but shorter radius whereas E haplotype generates a thinner 
and longer radius.  The effects of these haplotypes appear to be those of regulatory 
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gene(s) or element(s), which inhibit growth in one aspect while stimulating growth in 
another. These haplotypes are the ones that we are interested in charactering (Lark et al., 
2006; Chase et al., 1999; Chase et al., 2002; Carrier et al., 2005).  The SSR marker 
FH3585 is located approximately 39Mb from the centromere of CFA12 whose total size 
is 76Mbs.  Within 10Mbs around the marker FH3583, more detailed analyses of this 
particular QTL have been performed with additional SSR markers.  Two markers along 
FH3585 showed the strong association with this QTL at approximately 35Mbs and 
47Mbs from the centromere of CFA12, respectively.  Lark and colleagues suggest that 
this 12Mbs region between two markers may contain gene(s) or regulatory element(s) 
responsible for this trade-off phenotype in the limb bone (Lark et al., 2006; Chase et al., 
1999; Chase et al., 2002; Carrier et al., 2005).  However, because the downstream of 
CFA12 has not been fully characterized yet, it has not ruled out the possible makers that 
may be associated with this particular QTL at the downstream of CFA 12.  In fact, when 
the downstream of CFA 12 (i.e., the region after the 47Mb SSR marker) is surveyed, 
there are several candidates, such as different collagen genes, Ephrin receptors (Stadler et al., 2001), and transcription factor FoxO3 Kaufmann & Knochel, 1996: Lehmann, 2003) for instance, that may play an important role in bone formation.     
Longitudinal growth of bone depends mainly on the rate of production of 
hypertrophic chondrocytes from the proliferating chrondrocytes in a process of 
endochondral ossification (Karsenty, 2003; Kronenberg, 2003).  Endochondral 
ossification starts with the condensation of mesenchymal cells, which are adhered 
through the expression of adhesion molecules.  The aggregated mesenchymal cells 
differentiate into chondrocytes, the primary cells type of cartilage.  Expressions of the 
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adhesion molecules, N-cadherin and N-CAM, are induced by bone morphogenetic 
proteins (BMPs).  N-cadherin and N-CAM appear to be important for the initiation and 
maintenance of mesenchymal condensation (Adams et al., 2007; Kobayashi et al., 2007; 
Wu et al., 2007).  BMP is also responsible for inducting the expression of the 
transcription factor Sox9, which activates other transcription factors as well as the type II 
collage gene and the proteoglycan aggrecan (Adams et al., 2007; Kobayashi et al., 2007; 
Wu et al., 2007).  The chondrocytes go through rapid proliferation to form the cartilage 
model of the bone.  During their rapid proliferation, the chondrocytes produce and secrete 
a cartilage-specific extracellular matrix.  Then, the condrocytes in the center of 
condensation stop dividing, increase their volume radically, and become hypertrophic 
chondrocytes.  As the transformation of chondrocytes occurs, those cells change the 
synthesis of the cartilage-specific extracellular matrix by adding the collagen X, which 
enables the matrix to be mineralized by calcium phosphate. The hypertrophic 
chondrocytes secrete the angiogenesis factor, VEGF, and other factors to promote the 
invasion of blood vessels into the cartilage model (Karsenty, 2003; Kronenberg, 2003; 
Adams et al., 2007; Kobayashi et al., 2007; Wu et al., 2007).  Hypertrophic chondrocytes 
lead adjacent perichondrila cells to become osteoblasts, which secrete a specific matrix to 
generate a bone collar.  Then hypertrophic chondrocytes go through the apoptotic cell 
death.  Osteoblasts use the cartilage matrix that was left behind as a scaffold to invade the 
cartilage mould accompanied by blood vessels.  Eventually, osteoblasts put down a true 
bone matrix within it, which is known as primary spongiosa. While those activities of 
hypertrophic chondrocytes occur, the proliferation of chondrocytes continues in the 
mould and the mould therefore enlarges (Karsenty, 2003; Kronenberg, 2003; Adams et 
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al., 2007; Kobayashi et al., 2007; Wu et al., 2007).  A fraction of these proliferating 
chondrocytes changes the morphology to a flattened, discoid shape and stack themselves 
up with a clear orientation that promotes the lengthening of the bone.  As the bone 
elongates further, secondary ossification centers are set up when chondrocytes repeat the 
aforementioned process.  In the long bone of limbs, it is the region where the condrocytes 
continue to proliferate between primary and secondary ossification centres, which are 
defined as the growth plate.  At the top of the growth plate, some chondrocytes become 
round and slow down their proliferation.  These cells are known as reserve chondrocytes, 
which serve as precursors for the flat proliferating columnar chondrocytes (Karsenty, 
2003; Kronenberg, 2003; Adams et al., 2007; Kobayashi et al., 2007; Wu et al., 2007).  
Numerous signaling pathways and transcription factors including a BMP 
signaling pathway and Runx2 orchestrate the multiple events in the endochondral 
ossification. BMPs play multiple roles during bone formation.  For example, the type 1 
receptors BMPR1A and BMPR1B are expressed in embryonic mesenchyme and cartilage 
condensation, respectively (Adams et al., 2007; Kobayashi et al., 2007; Wu et al., 2007).  
When the BMP antagonist, Noggin, was expressed in early chick limbs, the mesenchyme 
failed to form the condensation (Pizette & Niswander, 2000).  Furthermore, the enlarged 
cartilage primordial was observed in Noggin-/-mice (Brunet et al., 1998).  Those studies 
indicate important roles of BMP signaling in formation of mesenchymal condensation.  
BMP2, 3, 4, 5, and 7 are expressed in perichondrium.  Expressions of BMP 2 and 6 are 
observed in hypertrophic chondrocytes.  BMP 7 also displays its expression in 
proliferating chondrocytes (Adams et al., 2007; Kobayashi et al., 2007; Wu et al., 2007).  
When BMPs were added to bone explants, proliferation of chondrocyates increased 
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whereas it inhibited with Noggin (Minina et al 2001, 2002).  Furthermore, terminal 
differentiation of hypertrophic chondrocytes was either delayed or hastened by BMP2 
and Noggin treatment, respectively (Minina et al 2001, 2002). Finally, studies of the 
mouse short ear (se) locus, which harbors numerous inactivating mutations of BMP5, 
displayed significant alterations in the size, shape, and number of many small bone and 
cartilage elements with other skeletal structures unaffected.  The signature phenotype of 
the se mouse carried is reduced size of external ears, which is caused by the defect in 
formation of mesenchymaal condensation (Kingsley et al., 1992; King et al., 1994). 
A transcription factor Runx2, a formerly known as Cbfa1, appears to be the 
master regulator in bone formation (Schroeder et al., 2005; Otto et al., 1997; Komori et 
al., 1997; Inada et al., 1999).  The expression pattern of Runx2 changes over time.  Runx2 
expression starts in the last condensation phase of chondrogenesis.  The expression 
significantly decreases in proliferating chondrocytes.  Then, the expression substantially 
increases in prehypertrophic and hypertrophic chondrocytes.  Also, high expression of 
Runx2 is identified in perichondrial cells and osteoblasts (Takeda et al., 2001).  Runx2 
mutant mice lack osteoblasts and also display defects in chondrocyte maturation.  The 
bone phenotypes observed in the mutant are either loss or significant decrease of 
hypertrophic chondrocytes and failure of matrix mineralization by the existing 
hypertrophic chondrocyte (Schroeder et al., 2005; Otto et al., 1997; Komori et al., 1997; 
Inada et al., 1999).  Moreover, the mutant mice showed an absence of the expressions of 
osteopontin and matrix metalloproteinase, which are normally expressed in late 
hypertrophic chondrocytes (Schroeder et al., 2005; Otto et al., 1997; Komori et al., 1997; 
Inada et al., 1999).  The transgene expression of Runx2 is capable of rescuing the 
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aforementioned phenotypes.  Overexpression of Runx2 seeded up the hypertrophy of 
normal chindrocytes and then stimulated hypertrophy and additional bone formation in 
cartilage that never usually experience hypertrophy, including tracheal rings.  The results 
mentioned above suggest that Runx2 regulates differentiation of hypertrophic 
choondrocytes and osteoblasts (Schroeder et al., 2005; Otto et al., 1997; Komori et al., 
1997; Inada et al., 1999).   
Significant roles of Runx2 and BMP signaling pathway in bone formation were 
described above.  Interestingly, both BMP5 and Runx2 are found at distant upstream 
(9Mb and 19Mb, respectively) of the QTL of interest in canine chromosome12.  It has 
been reported that developmental genes and transcription factors including BMP5 utilize 
distant regulatory elements to achieve its tissue-specific expressions (DiLeone et al, 
1998, 2000).        
In complex genomes such as those of human and mouse, many genes require a 
cis-acting element in genome to ensure temporally and spatially correct activation/ 
repression of gene expression.  Those cis-regulatory elements are defined as enhancer or 
repressor when the element activates or silences gene expression in a specific place (i.e., 
cell/tissue types) and certain time.  Enhancers and repressors can be found afar upstream 
or downstream of their core transcription units.  Those regulatory elements are also 
embedded within intron of genes.  Sometimes, these are located within an intron of a 
gene that is functionally unrelated to the regulated gene. To date, the distance between 
the cis-regulatory elements and its core transcription unit can be extended as much as 
1Mb (Dekker, 2008; Li et al., 2006; Kadauke & Blobel, 2008; West & Fraser, 2005; 
Bondarenk et al., 2003). 
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How a remote enhancer/repressor regulates its target gene remains unknown.  
However, it has been hypothesized that widely spaced regulatory elements (i.e., 
enhancers and repressors) in complex genomes can communicate with the target genes by 
conformation changes in chromosome that bring the remote regulatory elements and their 
target genes in proximity (Dekker, 2008; Li et al., 2006; Kadauke & Blobel, 2008; West 
& Fraser, 2005; Bondarenk et al., 2003).  It has been suggested that histone acetylation 
and other histone modifications modulate conformation changes in chromosomes, which 
makes chromatin form a loop.  Histone acetylation and other modifications seem to play 
key roles in determining the probability of interactions between distant regulatory 
elements and their target genes.  Several hypotheses of long-range communication 
between remote regulatory elements and their cognate genes have been put forward 
(Dekker, 2008; Li et al., 2006; Kadauke & Blobel, 2008; West & Fraser, 2005; 
Bondarenk et al., 2003; Miele & Dekker, 2008).  First of all, the simplest and the most 
attractive model is chromatin looping between the enhancer/repressor and promoters.  As 
described earlier, histone modifications lead to exposure of the preferential looping sites 
in chromatin, which determines the chance of interaction between remote 
enhancers/repressors and its target genes.  Second of all, according to a tracking or 
scanning model, once an enhancer recruits the transcription-activating complex, the 
complex linearly moves along chromatin until the complex meets its cognate promoter. 
This model does not involve the conformation changes in chromatin such as the 
formation of loop in order for the enhancers to interact its distant target promoters.  A 
third model is the facilitated tracking model, which combines aspects of chromatin 
looping and tracking model together.  According to the facilitated tracking model, an 
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enhancer and its transcription-activating complex travel along the chromatin until they 
encounter the target promoter.  While the transcription-activating complex with the 
enhancer migrates toward its target promoter, the chromatin fiber that the complex travels 
along is pushed out through the complex with the enhancer and creates a loop.  As the 
complex is skating along the chromatin, the loop gets enlarged.  Lastly, the linking model 
suggests that facilitator proteins that bind to a chromatin fiber between an enhancer and 
its target gene make a chain of facilitator protein, which may define the activated domain 
and mediate the communication between the enhancer and its cognate promoter (Dekker, 
2008; Li et al., 2006; Kadauke & Blobel, 2008; West & Fraser, 2005; Bondarenk et al., 
2003; Miele & Dekker, 2008). 
Although it remains unknown which model of communication remote regulatory 
elements utilize to regulate their target genes, many distant regulators have been 
identified over the years. Examples are the transcription factors, the winged 
helix/forkhead (FOX) genes and the bone morphogenetic proteins (BMPs). It has been 
suggested that a long-range control of the winged helix/forkhead (FOX) genes plays a 
critical role in ocular diseases among humans (Kleinjan & van Heyningen, 2005).  The 
FOX genes are a large family of transcription factors characterized by 100-amino-acid 
winged helix DNA-binding domain.  This family of transcription factors is involved in a 
wide range of developmental pathways including eye development.  FOXC1, previously 
known as FKHL7, is a part in a cluster of forkhead genes on chromosome 6p25 (Kleinjan 
& van Heyningen, 2005; Lehmann, 2003; Kaufmann & Knochel, 1996).  Mutations cause 
ocular malformations with iris or extra-ocular abnormalities and glaucoma 
(iridogoniodysgenesis type 1, IRID1).  In addition to ocular malformations with iris and 
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extra-ocular abnormality, the cardiac, renal, meningeal, skeletal and somite 
developmental defects in Foxc1 knockout mice and the spontaneous Foxc1 mutant, 
congenital hydrocephalus.  Those mutants demonstrate the diverse involvements of FOX 
genes in multiple organ developments.  Whether a number of copies of FOXC1 increases 
or decreases due to 6p25 segmental duplication and deletion, the phenotypes are very 
similar, which suggests that the precise gene dosage is crucial for normal eye 
development (Kleinjan & van Heyningen, 2005; Lehmann, 2003; Kaufmann & Knochel, 
1996).  Besides the intragenic point mutations and dosage effects for the FOXC1 gene in 
patients with IRID1, it has been reported that a patient suffering from primary congenital 
glaucoma carries a balanced translocation mapped 25 kb from the gene.  Also, it has been 
discovered that a patient with glaucoma and autosomal dominant iris anomaly was 
identified to harbor an interstitial deletion of 6p24-p25.  This deletion was approximately 
located at distance of 1200kb from the FOXC1 locus.  Those cases indicate that distant 
enhancers may regulate the tissue-specific expression of FOXC1 (Kleinjan & van 
Heyningen, 2005; Dekker, 2008; Li et al., 2006; Kadauke & Blobel, 2008; West & 
Fraser, 2005; Bondarenk et al., 2003; Miele & Dekker, 2008). 
FOXC2, another member of FOXC family, may possibly be regulated by the 
distant regulatory elements.  In development, Foxc2 plays a role in early mesoderm 
patterning.  Foxc2 knockout mice die of the skeletal genitourinary and cardiovascular 
defects, which is similar to Foxc1 homozygous knockout mice (Kleinjan & van 
Heyningen, 2005; Lehmann, 2003; Kaufmann & Knochel, 1996).  In humans, FOXC2 is 
located at chromosome 16q24.  FOXC2 mutations have been associated with 
lymphedema distichiasis (LD), which is an autosomal dominant disorder described by 
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lymphedema affecting the limbs and double rows of eyelashes (distichiasis). It has been 
reported that a patient suffering from neonatal lymphedema carries a translocation 
t(Y;16)(q12;q24.3) whose breakpoint is approximately at 120kb away from 3’end of 
FOXC2 gene.  The translocation apparently does not disrupt either genes on chromosome 
16 and any candidate gene on the Y chromosome (Kleinjan & van Heyningen, 2005; 
Dekker, 2008; Li et al., 2006; Kadauke & Blobel, 2008; West & Fraser, 2005; Bondarenk 
et al., 2003).  This strongly suggests a possible presence of tissue-specific regulatory 
element of FOXC2 at this particular breakpoint. 
The bone morphogenetic proteins (BMPs) are a large subclass of the transforming 
growth factor-β (TGF-β) family of secreted signaling molecules (Kingsley, 1994).  It has 
been shown that BMPs play a critical role in embryonic development such as dorsal-
ventral and left-right axis formation, mesenchymal-epithelial interaction and 
differentiation of many tissues including lung, gut, kidney, hair, teeth, cartilage and bone 
(Kingsley, 1994).  Lines of evidences indicate that some of BMP family members utilize 
distant cis-regulatory elements to accomplish precise spatiotemporal transcription 
(DiLeone, et al., 1998, 2000; Chandler et al., 2007).  Studies of the Drosophila 
decapentaplegic (dpp) have illustrated that several distinct and sometimes distant 
sequences specifically control dpp gene expression (Manak et l., 1994; Huang et al., 
1993).  Expression of the gene in the midgut is regulated by sequences positioned 5’of 
the gene.  Early embryonic expression is controlled by sequences in the intron.  Some of 
the dpp enhancers are placed more that 30kb away from the promoter in the considerably 
condensed fly genome (Manak et al., 1994). 
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In vertebrate, a spatial and temporal transcription regulation of BMPs has been 
extensively examined.  Among those, distant control elements of Bmp2 and Bmp5 have 
been identified (DiLeone, et al., 1998, 2000; Chandler et al., 2007).  For studies of both 
Bmp2 and Bmp5, LacZ reporter transgene approach was used to survey large regions of 
Bmp genes (106kb of 3’genomic DNA for the mouse Bmp5 and approximately 400kb 
surrounding the mouse Bmp2) and identify DNA sequences that can drive the expression 
of a reporter gene in Bmp expression domains.  Regulatory mutations and transgenic 
report studies for both Bmp2 and Bmp5 strongly indicated that a number of separated 
DNA sequences were positioned at separate genomic regions flanking either side of those 
genes (both 5’ and 3’ genomic regions for Bpm2 and 3’ genomic region for Bmp5) and 
those sequences are capable of regulating expressions of Bmp genes at specific 
anatomical locations in their designated tissues (DiLeone, et al., 1998, 2000; Chandler et 
al., 2007). cis-regulatory sequences that regulate Bmp2 expression in osteoblast 
progenitors were discovered in the distant 3’flanking region of Bmp2.  Bmp2 expression 
controlled by the potential osteoblast progenitor regulatory element closely follows 
expression of RUNX2 gene, the vital osteoblast factor.  This potential osteoblast 
progenitor regulator identified as well-conserved 656bp sequences that were located 
156.3kb from the Bmp2 promoter (Chandler et al., 2007).  For regulation of Bmp5 
expression, control elements in a distant 3’ region of Bmp5 gene, including manubrium, 
genital tubercle, thyroid cartilage, and lung mesenchyme, showed enormous specificity in 
the regulation of Bmp5 expression at specific anatomical locations in specific tissues 
(DiLeone, et al., 1998, 2000).  For instance, in the skeleton, regulatory sequences 
identified in 3’ genomic region of Bmp5 could drive a restricted reporter expression in the 
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upper region of a single bone at the top of the sternum (rostral manubrium).  Normal 
expressions of Bmp5 were seen in all the skeletal structures (DiLeone, et al., 1998, 2000).  
However, when a series of mutations were introduced into the 3’ genomic region of 
Bmp5, reporter gene expression was disturbed in specific parts of skeletal structures 
rather than in all the skeletal structures.  Finally, those regulatory sequences identified in 
the 3’region of Bmp5 were far apart from the Bmp5 promoter. In fact, the distance 
between the lung mesenchyme regulatory sequence and the Bmp5 transcription initiation 
site was more than 270kb (DiLeone, et al., 1998, 2000; Chandler et al., 2007). 
We hypothesize that this 40Mb-QTL contains gene(s) along with possible 
regulatory elements that are responsible for the length and width phenotype in the femurs 
of Portuguese water dogs.  In order to replicate the genetic mechanism of this particular 
bone phenotype and identify the gene(s) and possible regulatory element(s), we attempt 
to engineer the way to transfer the whole QTL into mouse embryonic stem cell by 
combining modern molecular techniques such as gene targeting, iPS cell technology and 
nuclear cell fusion technology.  Generation of QTL phenotypes seemingly requires 
involvement of multiple genes.  QTL of our interest, which spans in 40Mbs, may 
possibly harbor a group of genes generating this skeletal phenotype.  The best chance to 
generate the phenotype and identify the responsible gene(s) of interest efficiently may be 
to move a whole fragment in the environment where we are able to manipulate the 
fragment in the way we want.  Utilizing mice and their genetics enables us to do so 
because of advanced understandings of their genetics and available molecular tools.  
Transferring the QTL as a whole into mouse genome has another benefit, which is that all 
the canine transcription units and regulatory elements that are necessary for phenotypic 
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expression will be intact so that it will maximize the chance of generating the phenotype.  
It has been reported that transcript levels of mouse Prx1 increased in developing forelimb 
bones and significant elongations of forelimbs were observed when a limb-specific 
enhancer of mouse Prx1 was replaced by the orthologous sequence from a bat (Cretekos et al., 2008). Therefore, even if an enhancer or repressor is solely responsible for the 
strong phenotype in Portuguese water dogs, this canine skeletal phenotype in mice by the 
canine enhancer/repressor will possibly be expressed and identified.  
This project faces many major obstacles that have to be overcome.  First and 
foremost, there is neither canine cell line nor ES cell with this particular QTL. In order to 
achieve the recombination between mouse and dog chromosome and create the mouse-
dog chromosome with this specific QTL in mouse ES cells, the canine chromosome 12 
with this QTL must be altered by gene targeting the modifying Cre-Lox cassette of our 
choice to canine chromosome 12. It has been reported that efficiency of gene targeting in 
somatic cells is significantly reduced compared to ES cells because of cell senescence, 
lower overall rates of homologous recombination and higher rate of nonhomologous end 
joining (Brown et al., 1997; Arbones et al., 1994; Hanson & Sedivy, 1995; Waldman, 
1992). Therefore, it is necessary to have the canine ES cells that contain the QTL of 
interest in order to maximize the efficiency of gene targeting and the chance to make this 
project work. This requires us to generate canine ES cells from the fibroblasts harboring 
the QTL.  As introduced in Chapter 1, after the exhausting search for key factors to make 
ES cells out of fully differentiated cells among numerous factors involving in 
maintenance of stem cell pluripotency, Yamanaka and colleagues (Takhashi & 
Yamanaka, 2006) have found that combination of the four transcription factors, Oct4, 
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Sox2, Klf4 and c-Myc, is capable of turning somatic cells into the cells possessing 
pluriopotency when these factors are introduced into cells by retroviral virus.  Since these 
four factors can induce pluriopotency of a stem cell in any somatic cell, the technology is 
named iPS cell technology, which has been utilized in this project.  In this chapter I will 
focus on only on generation of canine ES cells out of the QTL-harboring fibroblasts and 
gene targeting in the canine immortalizing QTL-harboring fibroblast cells. 
 
Materials and methods 
Construction of the canine chromosome translocation vector 
To isolate the homology arms of the targeting vector, canine lambda DNA library 
was constructed by using Lambda FIX II kit (Strategene) as following the instruction of 
the company’s manual.  The genomic DNAs were isolated from the canine fibroblasts 
that carry both extreme phenotypes (short/wide leg and long/narrow leg).  The homology 
arms were identified by a canine DNA probe (F: 
catggcaacaaaatagcgaataaacgtttcccccagggcctgtctcagac; 
R:ggatttggtatcagttcaagataacctcggggcatgcaaacaccatggat  ).  The isolated homology arms 
were cloned into the recombineering vector (pStart-K-Dog) for further cloning process.  
The chromosome transfer cassette (CAG-Cre-IRES-Puromycin-5’half-Neo) was cloned 
into the pStart-K-Dog using engineered AscI-Pme-I sites.  After the completion of 
insertion of the chromosome transfer cassette, the vector was shuttled into the vector, 
pWS-TK by recombineering cloning.  pWS-TK contained the negative selection, TK, 




Construction of immortalizing Piggybac vector 
 Construction of the immortalizing piggyBac vector was described as following.  
hTERT was excised by NheI and SalI from pCI-Neo-hTERT (a gift from Dr. Robert 
Weinberg, MIT) and subcloned into engineered SpeI and XhoI of the shuttling vector, 
which has BglII and NheI sites engineered outside SpeI and XhoI.  SV40 large T antigen 
cDNA was excised from pSG5 Large T (Addgene; Plasmid 9053) by EcoRI and BglII 
and subcloned into EcoRI and BamHI of the shuttling vector engineered ClaI and SpeI 
outside EcoRI and BglII.  hTERT and SV40 large T antigen were excised by BglII/NheI 
and ClaI/SpeI and cloned into the CAGG promoter and EF1α of pVIVO4 (Invivogen), 
respectively.  Finally, EF1α-hTERT-CAGG-SV40 large T antigen was cloned into 
pStart-K engineered with AscI by recombination-mediated genetic engineering, excised 
and cloned into Piggybac vector (pSP72- PiggybacMiniM1) by using AscI.  
 
Preparation of canine primary fibroblast cells  
Tissue samples were taken from four adult Portuguese water dogs that carry two 
extreme ends of the phenotypes (i.e., two with shortest and widest femurs and two with 
longest and narrowest femurs).  Tissue samples were also collected from 3-month-old 
basset hounds that carry this particular QTL by ear punch.  For isolation of adult canine 
fibroblasts, the tissue samples were incubated with 1X trypsin/EDTA for 15 minutes at 
37°C and pipetted up and down a few times to dissociate the tissue during the incubation.  
After the inactivation of Trypsin/EDTA by fibroblast medium, the dissociated fibroblasts 
were plated and incubated at 37°C with 5% CO2 for further growth.  For the isolation of 
the neonatal canine fibroblasts, the tissue samples were incubated with 0.1% Collagenase 
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at 37°C overnight with gentle rocking.  After adding the fibroblast medium and settling in 
room temperature for a few minutes, the supernatant was collected and spun down for 5 
minutes at 1000rpm.  The dissociated fibroblast were re-suspended in the fresh fibroblast 
medium, plated and incubated at 37°C with 5% CO2 for further growth. 
 
Lentiviral and Piggybac constructs 
All mono-cistronic lentiviral stem cell vectors, FUW-Oct4, Sox2, Klf4, c-Myc , 
were obtained from Dr. Rudolf Jaenisch in MIT.  A single polycistronic lentiviral stem 
cell vector (pHAGE-EF1α-STEMCCA) was obtained from Dr. Gustavo Mostoslavsky at 
Boston University.  Lentiviral packaging vectors (Rev, Gag/Pol, VSV-G) for FUW-
lentiviral stem cell vectors and GFP-expressing lentiviral vector (CSII-EF-MCS-IRES-
GFP) were a generous gift from Dr.Eiji Morita at the University of Utah.  Lentiviral 
packaging vectors (pHDM-Hgpm2, tat1b, G-corrected, and pRC/CMV-rev1b) for 
pHAGE-EF1α-STEMCCA were obtained from Dr. Jeng-Shin Lee at Harvard Medical 
School. Piggybac stem cell vectors carrying either human or mouse Oct4, Sox2, Klf4, c-
Myc and Transposase-carrying vector (pKan-CAG-PBase) were generous gifts from Dr. 
Sen Wu at the University of Utah.          
 
Lentiviral production and infection 
The lentivirus was produced in HEK293T cells by calcium phosphate co-
transfection of lentiviral shuttle vectors with three viral packaging vectors (Rev, Gag/Pol, 
VSV-G).  For production of lentivirus by a single polycistronic lentiviral shuttle vector, 
additional viral Tat-expressing packaging vector was co-transfected with the single 
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polycistronic lentiviral shuttle vector.  The viral production by calcium phosphate co-
transfection in HEK293T cells was previously described (Miyoshi et al., 1998). Briefly, 
after co-transfetction of the viral vectors in HEK293T cells overnight (16-24 hour), the 
lentivirus was transduced in the fresh fibroblast medium (7.5ml) with 10µM Forskolin for 
48 hours at 37°C with 5% CO2.  After the lentivirus was transduced for 48 hours, the 
virus-containing medium was collected, filtered through 0.2-µm pore size cellulose 
acetate filter and concentrated by ultracentrifugation at 16,500 rpm at 4°C if necessary.  
The virus was collected every 24 hours starting 48 hours after the virus was transduced.  
Eight hundred thousand canine fibroblasts, which were seeded in 100-mm culture plates 
24 hours before the infection, were infected with filtered-concentrated virus in the 
presence of polybrene (5µg/ml).  The fresh virus/polybrene-containing medium was 
changed every 24 hours and the canine fibroblasts were infection every 4 days.  After 4 
days infection, the fibroblasts were washed with PBS three times and incubated in the 
fresh fibroblast medium for 48 hours with an exchange of the fresh medium in 24 hours.  
Then, the infected fibroblasts were trypsinized with 0.05% trypsin and re-plated onto 
either the MEF feeder cells or gelatin-coated plates with canine ES medium.  The canine 
ES medium was changed every 3 days.  The infected canine fibroblasts were watched for 
their morphological change to stem cell-like morphology over 24 days after re-plated.        
 
Cell culture 
Canine iPS cells were cultured either on mitotically inactivated mouse embryonic 
(MEF) feeders or gelatin-coated plates in canine ES medium.  Canine ES medium 
consists of Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F-12 medium 
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(Invitrogen); 15% fetal bovine serum (FBS) (HyClone); 0.1mM nonessential amino acids 
(Invitrogen); 1mM L-glutamine, 1mM sodium pyruvate (Invitrogen); 1U/ml, 1µg/ml 
penicillin/streptomycin (Invitrogen); human leukemia inhibitory factor (hLIF) (10ng/ml, 
Millipore).   Canine and murine fibroblast cells were always maintained in fibroblast 
medium, which consists of DMEM; 10% FBS; 0.1mM nonessential amino acids; 1mM 
L-glutamine, 1mM sodium pyruvate; 1U/ml, 1µg/ml penicillin/streptomycin. 
 
Southern blot 
Standard methods of Southern blot analysis were used to determine whether the 
chromosome translocation vector was incorporated into the beginning of QTL of interest.  
Southern blots were performed on DNA digested with NdeI for 5’ end and SpeI fro 3’ 
end of targeting site that cut once in genomic and the targeting vector internally and 
externally in order to determine whether the targeting vector was intact upon its insertion.  
When 5’ end of the targeted allele is intact, a 12Kb band is expected for the nontargeted 
allele whereas a 8kb band is expected for the targeted allele.  When 3’ end of the 
targeting allele is intact, a 10Kb band was expected for the nontargeted allele whereas a 
14Kb band is expected for the targeted allele Neomycin was re-probed on the Southern 
blot was previously performed for targeting detection to confirm transfection of the 
targeting vectors into cells.      
 
Transfection of Piggybac stem cell and immortalizing vectors 
Piggybac hTERT-SV40 immortalizing vectors with transposon containing 
plasmids were electroporated into 1x106 adult canine fibroblasts, which were trypsined 
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by 0.05% trypsin, were collected into 1ml of electroporation buffer in electroporation 
cubet and placed on ice until the time of electroporation.  The cells were placed and re-
suspended into the fibroblast culture medium immediately after the electroporation was 
complete.  Then, the cells were plated into 10cm culture plates and incubated at 37°C 
with 5% CO2.  The hygromycin selection was started 24 hours after the transfection and 
continued over 7-10 days before neomycin positive colonies were picked.  For the 
piggybac stem cell factor vector, the electroporation procedure and selection procedure of 
identifying the positive clones for stem cell factor vectors in the canine immortalized 
cells were the same as described above except Neomycin selection was used to select for 
the stem cell factor positive dog immortalized cells.   
  
Results 
Construction of the canine chromosome translocation vector (CCTV) 
It is essential to construct a targeting vector with the isogenic homology arm in 
order to maximize the targeting efficiency.  Canine lambda genomic libraries were 
constructed from two Portuguese water dogs with the extreme phenotype (i.e. the dog 
with the longest and narrowest femurs or the one with the shortest and widest femurs) to 
isolate the homology arms.  The results showed that the radiolabeled probe for the 
targeting gene, GLUD1 identified the correct clones (Figure 2-1 Top panels).  The 






Gene targeting of the CCTV into the canine immortalized  
fibroblasts 
Ten million of the canine immortalized adult fibroblasts were used for gene 
targeting of the canine chromosome transfer vector.  One hundred microgram of the 
targeting vectors were electroporated into those canine immortalized fibroblasts.  When 
the targeting vector was integrated into the targeted site (GLUD1) in the canine 
chromosome 13, a 4-kb downshift (14-kb for WT to 8-Kb for the mutant) would be 
observed on the southern blotting that probed by the 5’ canine DNA probe (Figure 2.1 
bottom panel).  A 4-Kb upshift should be observed on the southern blotting that was 
probed by the 3’canine DNA probe (Figure 2.1 bottom panel).  The results showed that 
the 5’southern blotting showed no targeted fibroblast was recovered out of the 500 clones 
(Figure 2.2 left panel).  Thus, the targeting of the chromosome transfer vectors did not 
occurred into the canine immortalized fibroblasts.  To check if the targeting vectors were 
actually introduced into these host cells by the electroporation, the southern blotting that 
was probed for the neomycin-resistance gene was performed.  The results of southern 
blotting showed the presence of the neomycin in those negative clones of the canine 
immortalized fibroblasts, which indicated that the electroporation worked properly to 
introduce the targeting vectors in the host cells (Figure 2.2 right panel).       
 
Reprogramming of the adult canine fibroblasts by iPS technology  
Gene targeting in the stem cells has been shown to be more effective than in the 
somatic cells.  Canine embryonic stem cells with this specific QTL are not available. 




   
Figure 2- 1. Lambda DNA library screening of the canine DNA homology arms.  
The red arrows indicate the positive clones that identified by the canine GLUD1 
probe (Top right).  Positive identification of the isolated lambda clones that contain 
the canine GLUD1 homology arms (Top left).  Southern Strategy to identify the 
targeted canine fibroblast clones.  The blue lines indicate the 5’end southern blot 
whereas the black lines show the 3’ end southern blot (Bottom panel). 
 
stem cells out of the somatic cells by virally introducing four transcription factors, Oct4, 
Sox2, Klf4, and c-Myc, into the somatic cells.  To explore this possibility, the adult canine 
primary fibroblasts were transfected with the lentivural vectors expressing these four 
reprogramming factors.  Fourteen days after the viral infection of these four factors, the 
transfected adult canine primary fibroblasts started to form the stem cell-like colonies on 









Figure 2- 2. Targeting to the canine GLUD1 in the canine chromosome 12.  
Southern blotting by the 5’canine DNA probe to detect the targeted integration of 
the targeting vectors (Left panel).  Neomycin detection in the canine immortalized 








the mouse ES cell colonies (Figure 2-3 bottom panels).  However, after a few passages 
these canine iPSCs had stopped growing.   
As described in Chapter 1, cell senescence is one of the major “roadblocks” to 
reprogram to pluripotency.  To overcome this reprogramming roadblock, the 
immortalized cells are often used to generate iPSCs.  Thus, the canine neonatal 
fibroblasts were isolated from the 3 month-old Beagles, which carried the QTL of 
interest.  These neonatal fibroblasts as well as the canine adult fibroblasts were 
immortalized by the piggyBac-hTERT-SV40 vector.  Although these canine 
immortalized fibroblasts emerged as the stem cell-like colonies, these canine stem cell-
like colonies appeared to be the intermediate iPSCs.  These colonies were never fully 
grown as observed earlier.  Interestingly, the canine iPSC population may be 
heterogeneous because the two distinct appearances of the canine (intermediate) iPSCs 
were observed in culture.  One looked like the mouse stem cells (Figure 2-3 top panels), 
whereas the other population looked like the canine ES cells, which was recently 




An overall goal of this project was to develop a new genetic technology that 
allowed us to transfer a large fragment of a chromosome between different species.  This 
genetic technology is the combination of a well-established technique, gene targeting 
with the Cre-Lox system, and a newly developing technique that enables the chromosome 







Figure 2- 3. Generation of the canine iPS cells from the canine primary adult 
fibroblasts (Top panels).  The mouse embryonic fibroblasts were used to generate 
mouse iPS cells as positive controls (Bottom panels).   
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Figure 2- 4.  iPSC formation from the canine immortalized neonatal fibroblasts by 
using the piggyBac reprogramming vectors.  The canine stem cell-like colonies were 
found during the reprogramming process (Top panels).  The images of the actual 






length and width was used as a model.  This chapter mainly describes the challenges in 
application of gene targeting in the canine cells.   
Gene targeting has been used in different cell types from different species (Mir 
and Piedrahita, 2004; Meehan et al., 2008).  In this project gene targeting was attempted 
in the adult canine fibroblasts.  Targeting efficiency is extremely low in primary somatic 
cells because of cell senescence, lower overall rates of homologous recombination and 
higher rate of nonhomologous end joining (Brown et al., 1997; Arbones et al., 1994; 
Hanson & Sedivy, 1995; Waldman, 1992).  To overcome these problems and succeed in 
gene targeting, the canine adult fibroblasts were immortalized by coexpression of hTERT 
with SV40 largeT antigen because the stable transfection of hTERT alone was not 
sufficient to immortalize the primary canine fibroblasts.  It has been reported that co-
expression of hTERT with SV40 LargeT antigen was capable of immortalizing the 
primary cells that were difficult to transform without damage to the genome, such as 
genomic shuffling (O’Hare et al., 2001).  
As the results showed, the chromosome transfer vectors were indeed introduced 
into the canine immortalized fibroblasts, but the genomic incorporation of the vectors 
was always random.  Although gene targeting can be successfully performed in 
immortalized somatic cells from different species, the success of gene targeting in the 
immortalized somatic cells requires modifications, including cell-cycle synchronization 
and the addition of the nuclear localization sequences (Mir and Piedrahita, 2004; Meehan 
et al., 2008).  Even with the modifications, the efficiency of gene targeting is extremely 
low in those somatic cells compared to the targeting efficiency in mouse embryonic stem 
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cells (Mir and Piedrahita, 2004; Meehan et al., 2008).  For success of this entire project, it 
is essential to obtain the canine embryonic stem cells with the QTL of our interest.   
Recent invention of iPSC technology has enabled researchers to generate stem 
cell-like cells from the somatic cells of different species such as mice, rats, and humans 
(Takahashi and Yamanaka, 2006; Liao et al., 2009; Takahashi et al., 2007).  iPSC 
technology was tried in the adult canine fibroblasts to see if canine iPSCs could be 
generated.  The initiation of canine iPSC generation was observed yet those iPS cells 
stopped growing after they were isolated by using trypsin, which reportedly harmed the 
canine embryonic stem cells during their isolation (Vaags et al., 2009; Hayes et al. 2008).  
Although an alternative enzyme dispase was used for the isolation of the canine iPSC 
colonies later on, the canine adult fibroblasts could be partially reprogrammed but could 
not complete the reprogramming process.   
The process of iPSC generation has two phases: iPSC generation phase and 
maintenance phase.  In each phase, specific molecular and genetic events must occur in 
the cells in order for the cells to obtain the full pluropotency as fully competent iPSCs 
(Feng et al., 2009; Jaensch and Young, 2008).  It has been identified that the number of 
small molecule inhibitors are capable of promoting each phase of iPSC generation (Feng 
et al., 2009).  A triple cocktail of valproic acid, sodium butyrate and vitamin C (termed as 
3i) has worked the best to promote each phase (personal communication with Dr. Wu, 
University of Utah).  Even with the supplement of the 3i, the canine adult fibroblasts 
never become the fully competent iPSCs.     
Both the mouse and the human iPSC four factors were tried to generate the canine 
iPSCs.  However, neither the mouse nor the human factors could complete the 
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reprogramming processes in the canine primary fibroblast or the immortalized 
fibroblasts.  Possibly, neither the mouse nor the human reprogramming factors were 
compatible to the canine transcriptional machinery.  Shimada and colleagues recently 
demonstrated the first success of the canine iPSC generation (Shimada, et al., 2010).  
Importantly, Shimada and colleagues used canine Oct4, Sox2, Klf4, and c-Myc with the 
small molecule inhibitor, valproic acid to generate the canine embryonic fibroblasts 
(Shimada et al., 2010).  Canine iPSCs could be generated from the canine adult 
fibroblasts if these fibroblasts were reprogrammed by the canine Oct4, Sox2, Klf4, and c-
Myc with the supplement of 3i (valproic acid, sodium butyrate and vitamin C).  In sum, 
both applications of gene targeting and iPSC techonology to canine immortalized 
fibroblasts were unsuccessful because of the possible reasons described above.  However, 
with technical improvements described above, both gene targeting and canine iPSC 
formation will be achievable in the future.            
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CHARACTERIZATION OF A NOVEL GENE, AK045681  
IN MOUSE BRAIN 
 
Introduction 
The mammalian central nervous system (CNS) is made up of diverse neuronal 
cell types, which is the reflection of the complexity of gene expression profiles that are 
present in the brain.  The human genome project has revealed that the human genome 
consists of nearly 30,000 genes of which almost one third to one half are particularly 
expressed in the brain and for which the biological roles of the vast majority remain 
unknown (Diaz, 2009; van der Burg et al., 2010).  A number of mutagenesis techniques 
are available for generating mutant mice, including chemical-induced mutagenesis, 
radiation-induced mutagenesis, and gene targeting.  Each of these techniques is very 
powerful and each has its own advantages and disadvantages.  For example, chemical 
mutagens such as ethyl-nitrosourea (ENU) produce random single base-pair changes 
throughout the genome with a high frequency of mutant phenotypes (Carlson & 
Largaespda, 2005).  With this technique, however, researchers have no control over the 
introduction of the mutations.   Also, this technique lacks useful molecular markers for 
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easy identification of the mutation responsible for the phenotypes.  Gene targeting allows 
researchers great specificity for introducing the mutation of interest using molecular 
markers.  As revolutionary and useful as this technology is, gene targeting can be
technically challenging in terms of engineering the targeting vectors.  Low targeting 
efficiency, frequent random integration of vectors, ES cell work and generations of 
mutant mice also make gene targeting more challenging and time-consuming (Carlson & 
Largaespda, 2005).  To uncover biological functions of those unknown genes in the brain, 
high throughput mutagenesis approaches with high efficiency and site specificity of the 
vector integration will be required.   Transposable elements or transposons are mobile 
genetic elements that move around via a “cut-and-paste” mechanism within the genome 
of an organism (Copeland & Jenkins, 2010; Izsvak & Ivics, 2004; Mates et al., 2007:  
Carlson & Largaespda, 2005).  Because of their ability to insert themselves close to or 
within genes, transposons can be used to inactivate genes through insertional 
mutagenesis.  This provides researchers with information about the function of the genes.  
Transposable elements have been modified and utilized as effective germ-line 
transgenesis and insertional mutagenesis in invertebrates such as flies and worms 
(Copeland & Jenkins, 2010; Izsvak & Ivics, 2004; Mates et al., 2007:  Carlson & 
Largaespda, 2005).  However, no functional transposon in vertebrate had been reported 
until the recent resurrection of the active Tc1-like DNA transposon, Sleeping Beauty 
(SB), from salmoind fishes by comparative phylogenic approach (Ivics, et al., 1997).  
Following the discovery of SB, a new DNA transposon, piggybac (PB) was discovered 
from the cabbage looper moth and proven to be functional in mammalian genomes such 
as mice and humans (Ding et. al, 2005).  Both SB and PB do not integrate randomly into 
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target DNA and both show specificity of integration site such as TA dinucleotide for SB 
and TTAA tetranucleotide for PB (Copeland & Jenkins, 2010; Izsvak & Ivics, 2004; 
Mates et al., 2007:  Carlson & Largaespda, 2005; Ding et. al., 2005).  PB has great 
functional advantages over SB.  It has been shown that upon excision of the transposable 
elements, SB leaves a 3-bp transposon “footprint” because of its excising mechanism 
(Copeland & Jenkins, 2010; Izsvak & Ivics, 2004; Mates et al., 2007:  Carlson & 
Largaespda, 2005).  The precise excision of the PB transposon mechanism, however, 
leaves no “footprint” behind (Ding et al., 2005; Thibault et al., 2004; Fraser et al., 1996; 
Elick et al., 1996).  Furthermore, SB exhibits a strong tendency for local hopping.  Local 
hopping is the phenomenon that the transposons preferentially reintegrate near its original 
insertion site upon excision of the transposons from the genome.  In contrast, PB does not 
display any propensity for local hopping (Copeland & Jenkins, 2010; Izsvak & Ivics, 
2004; Mates et al., 2007:  Carlson & Largaespda, 2005; Ding et. al., 2005).  PB is capable 
of carrying a much larger cargo (up to 20-kb) in its transposon vector than SB is (up to 
10-kb) (Copeland & Jenkins, 2010; Izsvak & Ivics, 2004; Mates et al., 2007:  Carlson & 
Largaespda, 2005; Ding et. al., 2005).  Finally, it has been reported that piggybac can be 
encoded by transgenes and expressed via inducible or tissue-specific promoters to 
mobilize unlinked transposons in a regulated manner (Wu et al., 2007; Cadinanos & 
Bradley, 2007). Given the flexibility of molecular engineering, insertion specificity, and 
high transposition activity, piggyback shows great potential as a tool for mammalian 
transgenesis with the possibility of targeted integration.        	                    
Wu and colleagues have improved the gene-trap method with the piggybac 
transposon system.  They identified the minimum length of the inverted terminal DNA 
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repeats requiring the highest transposition efficiency.  They also elegantly designed their 
gene trap construct, which included β-gal reporter and constitutively expressed eGFP 
with a combination of Lox sites and FRT site.  The β-gal expression reports an activity of 
the gene that the gene-trap cassette disrupts, and the constitutively expressed eGFP serves 
as a convenient marker for identification of new transposition in vivo.  Most importantly, 
their versatile gene-trap construct can be conditionally excised by tissue-specific Cre 
expression so that the normal function will be “rescued” from the loss of the function 
state in the tissues of interest (Wu et al., 2007).  Their piggybac gene trap screening in 
mice mutagenized an interesting novel gene, AK045681.   
A novel gene locus, AK045681 is located in chromosome 12 in the mouse 
genome.  It is made out of four exons.  Exons 1 through 3 of this novel gene consist of a 
large 5 prime untranslated region (approximately 1100-bp), whereas exon 4 harbors the 
open reading frame, which is translated into 120 amino acids (AAs).  Although the 
biological function of this small protein remains unknown, it has been speculated that 
AK045681 may play a role in RNA splicing, based on the AAs sequence similarity of 
AK045681 to the spliceosomal protein U1C.  The spliceosomal U1C protein plays a 
critical role in the initiation and regulation of pre-mRNA splicing as a component of the 
U1small nuclear ribonucleoprotein particle (Patel & Steitz, 2003; Wahl et al., 2009).  
U1C consists of unusual proline and methionine-rich residues in the carboxy terminus 
and several cysteines and histdines in the amino terminus.  These cysteine and histidine 
residues are arranged to form a zinc finger-like domain, which is known to be involved in 
protein-nucleic or protein-protein interactions (Nelissen et al., 1991; Forch et al., 2000, 
2002; Muto, et al., 2004).  AK04681 does not possess the zinc finger-like domain; 
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however, it does contain particular proline and methionine-rich sequences (PRS).  The 
PRSs motifs are recognized by proline-rich sequence recognition domains (PRD) such as 
SH3, EVH1, GYF, UEV and WW domains (Kofler et al., 2009; Kofler & Freund, 2006).  
Complexes of PRS/ PRD are widely used by nature in higher eukaryotes and have 
participated in numerous biological processes including ubiquitin-mediated protein 
degradation, transcription, RNA processing, and cytoskeletal regulation (Kofler & 
Freund, 2006; Ingham et al., 2005).    Frequently, the PRS motifs are found in splicing 
factors and spliceosomal proteins including the U1C, SmB/B’, branch point-binding 
proteins and U5snRNP-asscociated protein (Kofler et al., 2004; Abovich and Rosbash, 
1997; Wiesner et al., 2002).  The PRS motifs provide docking sites for the PRDs (e.g., 
GYF and WW domains) and likely help the formation of the spliceosome.   For example, 
the branch point-binding protein (BBP) in yeast and splicing factor 1 (SF1) in humans are 
RNA-binding proteins known to bind the branch point sequence during RNA splicing 
(Bedford et al., 1997).  It has been shown that the carboxy terminus of BBP contains 
PRS, which is associated with Prp40 (pre-mRNA processing protein 40), a part of the 
U1snRNP in yeast (Abovich and Rosbash, 1997).  The PRS of human SF1 is also known 
to bind to the WW domain of FBP1 (formin-binding protein 1), the vertebrate homologue 
of Prp40 (Bedford et al., 1997).  The splicing factor SIPP1 (Splicing factor that Interacts 
with PQBP-1 and PP1) has two PRS regions, which are able to interact with the WW 
domain of PQBP1 (polyglutamine tract-binding protein 1), and act as pre-mRNA splicing 
activators in intact cells (Llorian et al., 2004, 2005).  Furthermore, it has been shown that 
SIPP1 also interacts with the WW domain of the human FBP21, and functions as a pre-
mRNA splicing activator in vivo (Huang et al., 2009).  As stated above, the presence of 
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PRS motifs in AK045681 and the similarity in AA sequences between the spliceosomal 
U1C protein and AK045681 have led me to hypothesize that pre-mRNA splicing has a 
potential biological role in AK045681.      
This chapter describes the cellular and functional characterization of the novel 
gene, AK054681 in mice.  The present study shows that AK045681 is postnatally 
expressed in GABAergic neurons in the specific neuronal regions (e.g., the amygdala and 
the hippocampus) that regulate anxiety-related behaviors.  Neuronal nuclear co-
localization of this novel gene to the spliceosomal SmB/B’ protein supports the potential 
role of AK045681 in pre-mRNA splicing as a splicing factor, or a part of the 
spliceosome. Finally, disruption of AK045681 in mice causes interference of the 
expression of anxiety-related behaviors.    
 
Materials and methods 
Animals 
Generation of AK045681 mutant mice was described elsewhere (Wu et al., 2007).  
A gene-trap vector, ZG-s consisted of IRES-β-galactosidase-pA and CAG-eGFP-pA 
cassette flanked by LoxP sites with the minimum LTRs.  The minimum LTRs are 
required for the transposition.  The entire cassette would be excised by mating with Cre-
expressing mice for conditional rescue allele.  The CAG-eGFP-pA cassette was flanked 
by FRT sites that can be excised by mating with Flpe-expressing mice at the researcher’s 
convenience.  Both ZG-s and piggyBac transposase-expressing construct were used for 
pronuclear injection to create the transgenic mouse lines.  The insertion site of the gene-
trap vectors was identified by inverse PCRs as described (Wu et al., 2007).    
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Cortical neuronal culture and DNA transfection  
Mouse embryos  (E13.5) were used to isolate the cortical neurons.  Pregnant 
C57BL/6 female mice were sacrificed by cervical dislocation and the fetuses were 
transferred to sterile PBS.  The cortices were dissected from the fetuses and single-cell 
suspension of the cortical cells was prepared by papain digestion followed by trituration 
through a P-1000 pipette and DNaseI treatment.  The single-cell suspension of the 
cortical cells was washed by the dissection medium (Neurobasal medium with B12) and 
spun down at 1000rpm for 5 minutes twice.  The isolated cortical cells were re-suspended 
in the neuronal culture medium (Neurobasal medium with B12 and bFGF) and were 
plated onto the poly-L-lysine coated culture dishes (Thermo Scientific).   
The cortical neurons were transfected with either a plasmid carrying full-length 
cDNA of AK045681 or a spliced variant of AK045681cDNA.  X-tremeGENE HP DNA 
transfection reagent (Roche) was used to transfect the aforementioned plasmids to the 
cortical neurons.  The procedure was performed as the manufacture’s instructed.  Briefly, 
the DNA plasmids were diluted with serum-free medium to a final concentration of 1µg 
DNA per 100µl medium.  The X-tremeGENE HP DNA transfection reagent (4:1 reagent 
to DNA ratio) was directly added to the medium with the diluted DNA plasmids.  The 
transfection reagent/DNA complex was incubated for 15 minutes at room temperature 
before it was applied to the neurons in a dropwise manner.  The cultured neurons were 
incubated with the transfection reagent/DNA complex for 48 hours before the further 






Total RNAs were isolated from the whole brains of AK045681 mutant mice and 
their wild type littermates (postnatal day 15 or older) with TRI Reagent (Molecular 
Research Center, Inc) by following the manufacture’s instruction.  Poly (A) mRNAs were 
further isolated from those total RNAs by using Dynabead-oligo (dT) (invirogen).  
Standard northern blotting was performed as described elsewhere (Sambrook and 




Reverse transcriptase PCR 
Total RNAs were isolated from the whole brains of AK045681 mutant mice and 
their wild type littermates (postnatal day 15 or older) by TRI Reagent (Molecular 
Research Center, Inc) by following the manufacture’s instructions.  Any contaminating 
DNA was removed by DNseI treatment from the RNA preparation.  Complementary 
DNA of AK045681 was synthesized with Superscript II reverse transcriptase 1st strand 
cDNA according to the manufactures’ instruction.  One microgram of RNA from each 
sample was used in each 20ul RT reaction, and 2ul of the cDNA products were used as 
template in each 20ul PCR reaction.  The primer sequences for exon 3-4 transcript are: 






In vitro translation  
A reticulocyte lysate system and nonradioactive translation detection system 
(Promega) were used to translate AK045681 full-length and spliced cDNAs in vitro 
according to the instructions from the manufacture.  Briefly, an equal concentration (1µg) 
of each cDNA was added to the reticulocyte lysate transcription/translation system with 
biotinylated lysine t-RNA molecules.  The reactions were incubated at 30°C for 1 hour.  
After the reactions were completed, the products were ran in SDS-PAGE gel and 
transferred into the PVDF membrane.  The membrane was incubated in TBST for 60 
minutes followed by incubation with streptavidin-AP at room temperature for another 
hour.  After the completion of streptavidin-AP binding, the membrane was treated with 
the substrate for alkaline phosphate until the bands of interest emerged.   
      
X-gal staining  
For the whole mount X-gal staining the brains were taken out at the appropriate 
time of development.  The brains were incubated in the LacZ fixative (1% formaldehyde, 
0.2% gluteraldehyde, 2mM MgCl2, 5mM EGTA, 0.02% Nonidet P40 (NP40) in PBS) for 
20 minutes at 4°C.  After fixation, the brains were washed three times (20 minutes each) 
with PBS at room temperature.  After the wash, the brains were incubated in the staining 
solution (5mM potassium ferricyanide, 5mM potassium ferrocyanide, 2mM MgCl2, 
0.01% sodium deoxycholate, 0.02% NP-40, 1mg/ml X-Gal in PBS) and kept in the dark 
at 4°C overnight. After the staining was completed, the brains were washed twice (15 
minutes each) with PBS at room temperature and stored in 70% ethanol until analyzed.   
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For the X-gal slide staining, the brains were fixed for 4 hours with rocking at 4°C.  
After the fixation, the brains were washed three times with the wash buffer following by 
three washes with PBS.  Then the brains were cryoprotected in 15% sucrose/PBS for 1 
hour followed by the cryoprotection in 30% sucrose/PBS overnight at 4°C.  The samples 
were embedded into the embedding medium (Tissue-Tek; Sakura Finetek) and sectioned 
at 10-µm thickness.  The sectioned samples were incubated in the LacZ staining solution 
for 4-6 hours at 37C and washed three times in PBS.  Finally the sectioned samples were 
dehydrated from 50% to 100% ethanol and cover slipped.    
 
Immunostaining  
Immunostaining was carried out on 10-µm sections using the following primary 
antibodies: anti-β-galactosidase (rabbit & chicken; 1:250; Abcam), anti-NeuN (mouse; 
1:1000; Millpore), anti-GFAP (mouse; 1: 250; Covance), anti-MBP (mouse; 1:250; 
Covance), anti-calbindin (mouse; 1:250; Swat), anti-GABAaRα6 (rabibit; 1:500; 
Millipore), anti-GABA (g-pig; 1:500; Abcam).  Primary antibodies were detected with 
secondary antibodies labeled with Cy3, or FITC (1:1000; Invitrogen).  Primary antibodies 
used for immunostaining of the cultured neurons and mouse embryonic fibroblasts were 
the following: mouse monoclonal anti-HA (1:1000, Covance), mouse monoclonal anti-
Tuj1 (1:200, Covance), rabbit polyclonal anti-SmB/B’/N (1:500, Santa Cruz 
biotechnology).  Primary antibodies were detected with secondary antibodies labeled 
with Cy3 or FITC (1:1000; Invitrogen).  DAPI was used for the nuclear staining.   





Metric spatial processing task 
The protocol was adapted from Goodrich-Hunsaker, et al., (2005, 2008b).  The 
metric spatial processing task was performed on a circular table measuring1m in 
diameter.  The table was covered with a clean, clear plastic cover.  Four objects were 
used as stimuli in the task (small bottle filled with red liquid, an overturned coffee mug, a	 
large pencil stand, and a floating orange duck).  Those objects measured between 2.5-5 
cm at the base and between 5 and 15 cm tall, and were chosen to be textually and visually 
unique and easy to distinguish for mice.  The table was surrounded on four sides by walls 
(at a distance of ~1 m) with discrete distal cues available at the same level as the table 
surface affixed to the wall.  The mice were placed back in their home cage between the 
habituation and test period.  The circular table was wiped down with 70% ethanol after 
testing of each mouse to remove any trace of olfactory cue that could affect object 
exploration by mice tested later.  The two objects were placed 45 cm apart on the circular 
table.  The mouse was allowed 15 minutes to freely explore the tabletop, stimulus objects 
on the table and distal environmental cues.  After a 15-minute habituation period, the 
mouse was placed back in the home cage for 5 minutes.  During the intermission the 
objects were moved closer to each other so that the distance between the objects was 30 
cm.  The mouse was placed back onto the table again to re-explore the objects for 5 






Topological spatial processing task  
The procedure of the topological spatial task was described elsewhere (Goodrich-
Hunsaker, et al., 2005, 2008b; Lee et al., 2009).  The topological spatial processing task 
was performed on the behavioral apparatus described above.  Two novel objects that 
were different from those used in the metric spatial processing task were used as stimuli.  
Mice were placed on the table and allowed to explore exactly for 15 minutes as in the 
metric spatial processing task.  During the intermission of the experiment the positions of 
objects on the table were switched (i.e., the object on the left in the habituation period 
was now placed on the right and vise versa).  The spatial locations of two objects were 
the same as in the habituation period but the positions of two objects were exchanged in 
the testing period.  For both the metric and topological spatial processing task, time that 
mice spent to explore each object was recorded.  The operational definition of exploration 
was that mice actively sniffed or touched the objects with the nose, vibrissa or forepaws.   
 
Rota-rod motor learning task 
The Rota-rod motor learning task is described elsewhere (Homles et al., 2001).  
The Rota-rod motor learning task consisted of four trials (three training sessions plus pre-
training) per day over 4 consecutive days. Each training trial lasted for 5 minutes, and the 
intertrial interval was for 20 minutes.  Mice were acclimated to the behavioral room for 
30 minutes before the task began.  As the pretraining session, the rotation speed of the 
rod was set to 4rpm constant speed.  The mice were placed onto the rod and must keep 
their balance for 60 seconds. The mice were put back onto the rod when they fell off the 
rod before the time expired.  The mice must stay on the rod for 60 seconds successfully to 
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pass the pretraining. The purpose of the pretraining was to get them accustomed to the 
task.  After the pre-training session, the mice were placed back to their home cages and 
rested for 30 minutes.  After a 30-minute break, the training sessions began.  The mice 
were put back onto the rod, which was set to accelerate from 4rpm to 35rpm in 300 
seconds.  The mice were moved back into their home cages after they fell off the rod.  
The latency for the mice to fell off the rod was recorded.  The Rota-rod apparatus was 
wiped clean with 70% ethanol and dried well between the trainings. 
 
Elevated plus maze 
The protocol of the elevated plus maze was described elsewhere (Walf & Frye et 
al., 2007; Holmes et al., 2002).  Briefly, the elevated plus maze consists of four arms (two 
open arms without walls and two closed arms with 15.25 cm high walls).   Each arm of 
the maze is 30 cm long and 5 cm wide and is attached to solid metal legs, which elevate 
the maze 60 cm off of the stage that the maze is on.  Thirty minutes before the behavioral 
tests were performed, mice were transferred to the behavioral test room and acclimated to 
the room where the test was administrated.  Mice were placed in the interaction of the 
four arms of the maze facing an open arm.  The exploratory behavior of mice was 
detected by a video-tracking system (Any-Maze, Stoelting) for 5 minutes.  Entries and 
durations in each arm (open, closed arms and intersection) were recorded by the video 
tracking system.  The video tracking system also recorded distance that mice travelled in 
each arm.  The maze was wiped clean with 70% ethanol and dried well before testing 





AK045681 is knocked out by the piggybac DNA transposon system 
RT-PCR analysis and northern blotting were performed to identify the presence of 
AK045681 transcripts in the AK045681 KO mice.  RT-PCR showed that AK045681 
mRNA was not present in the brains of the AK045681 null mutant mice when mRNA of 
AK045681 was amplified by using the primer pair designed for the exon3-exon4 
sequence (Figure 3-1).  On the contrary, RT-PCR analysis demonstrated the presence of 
AK045681 mRNA in the WT littermate mice when AK045681 mRNA was amplified 
using the same primers above (Figure 3-1).  Because the open reading frame (ORF) of 
AK045681 is located only in exon 4, RT-PCR analysis was performed to see if the 
AK045681 transcripts with exon4 were eliminated in the AK045681 null mutant mice. 
The results of RT-PCR unexpectedly showed the presence of mRNA of exon4 in the 
AK045681 mutant and the WT littermate mice, although the amplified band for the 
mutant mice was much less intense than the one for the WT mice (Figure 3-1).  To verify 
the results of the RT-PCR, the northern blotting was performed by using probes for exon 
3-4 and exon 4 only.  The results showed the presence of both exon3/4 or exon4 of 
AK045681 in the WT littermate mice, but neither transcript was present in the AK045681 
KO mice (Figure 3-1).   
Our piggybac DNA transposon cassette carries IRES-LacZ, which is expressed as 
AK045681 is.  Therefore, LacZ serves as the marker of AK045681.  Whole mount X-gal 
staining of the brains of AK045681 mutant mice revealed the timing of AK045681 
expression in brain.  As Figure 3-2 shows, AK045681 started to express on postnatal day 




Figure 3- 1. RT-PCR and northern blotting of AK045681 transcripts in mouse 
brain.  RT-PCR analyses (Top-left panel) showed that no AK045681 transcript 
containing Ex3/4 was detected whereas a little trace of AK transcripts with ex4 
(ORF-harboring) in AK045681 null mutant mice.  Northern blotting (bottom 
panels) showed no detection of both AK transcripts (ex3/4 and ex4 only).  AK045681 
is expressed postnatally (postnatal day 12) in the hippocampus, amygdala, cortex, 
cerebellum, hypothalamus and anterior olfactory nucleus.            
 
 





Figure 3- 2. Whole mount X-gal staining of the brains of the AK045681 null mutant 
mice.  X-gal staining was detected in the whole brain of the AK045681 null mutant 
mice at postnatal day 12 (Top-right) whereas no staining was detected in the whole 
brain of the AK045681 null mutant mice.  The sagittal (middle-panel) and coronal 
(bottom-panel) view of the whole brain showed the X-gal staining in specific neural 
regions in the brains of the AK045681 null mice.   
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The X-gal staining of the whole brains showed that AK045681 was expressed in specific 
brain regions such as the cortex, hippocampus, amygdala, olfactory system, and the 
cerebellum.  The X-gal staining of individual brain sections showed more cellular 
detailed expression of AK045681.  The strong expression of AK045681 was observed in 
the CA regions of hippocampus.  The superficial layers of the cortex showed the intense 
X-gal staining.  In the cerebellum, the inner granular layer and the Purkinje cell layer 
showed the expression of AK045681.  The X-gal staining confirmed the strong 
expression of AK045681 in the brain regions including the amygdala. Additionally, the 
expression of AK045681 was observed in the striatum, which was not observed on the 
whole mount X-gal staining of the brains (data not shown). 
   
AK045681 is expressed and localized in the nucleus of GABAergic  
neurons in the mouse brain 
As Figure 3-3 shows, co-localization of AK045681 with NeuN was detected in 
the brains of the AK045681 null mutant mice.  The expression of AK045681 was mainly 
observed in pyramidal cell layer of the hippocampus.  Co-localization of AK045681 and 
GABA was detected in the pyramidal cell layer of the hippocampus.  Double 
immunostaining of AK045681 and GABA was also found in other AK-expressing brain 
regions including the cortex, the anterior olfactory nucleus, the striatum (data not shown), 
and the amygdala (data not shown). Co-localization of AK045681 and Purkinje cell 
specific marker Calbindin validated the expression of the AK045681 in the Purkinje cells 




Figure 3- 3. AK045681 is expressed in the GABAergic neurons in different neuronal 
substrates in the mouse brain.   Co-localizations of β-gal (Green) and GABA (Red) 
were detected in the cortex (Top-left), the anterior olfactory nucleus (Top-middle), 
and the hippocampus (Top- right).  AK045681 is also expressed in Purkinje cells 
(Green: Calbindin, Red: β-gal, Bule; DAPI) and granular cells (Green: GABAaR 
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subunit α6, was co-localized with AK045681, which confirmed the expression of 
AK045681 in the granule cells in the inner granular cell layer of the cerebellum.   
The amino acid sequence of AK045681 is similar to the spliceosomal protein 
U1C.  This suggests that AK045681 may play a role in RNA splicing and maturation.  
RNA splicing by the spliceosome occurs in the nuclei of cells.  Localization of 
AK045681 in the nucleus of cell would be the further indication that the AK045681 may 
be involved in RNA splicing and maturation.  Co-localization of HA-tagged AK045681 
protein and DAPI nuclear staining demonstrated the localization of AK045681 in the 
nucleus of the mouse fibroblasts transfected with HA-tagged-AK045681 ORF plasmids 
(Figure 3-4).  Furthermore, the co-localization of AK045681 with DAPI nuclear staining 
was also observed in the nucleus of the HA-AK045681-ORF transfected mouse cortical 
neurons (Figure 3-4). Additionally, the nuclear spliceosomal protein, SmB/B’/N, was 
used to validate the nuclear localization of AK045681. Triple immunostainings of HA-
tagged AK045681, SmB/B’/N, and DAPI, showed nuclear co-localization of AK045681 
in mouse fibroblasts (Figure 3-4).    
 
AK045681 is translatable in vitro  
AK045681 has two forms of its transcripts, a full-length and a splicing variant, 
which is the lack of exon 2-3 of AK045681.  To determine whether the transcripts of 
AK045681 are indeed translatable in vitro, cDNAs of those two forms of AK045681 
were transcribed and translated in the reticulocyte lysate.  As Figure 3-5 shows, both the 
full-length and the spliced variant of AK045681 were translated in vitro, which indicated 






Figure 3- 4. The nuclear localization of AK045681 in the mouse fibroblasts (MEFs) 
and cortical neurons.  In MEFs (Top panels) the HA-tagged AK045681 (Green: HA) 
co-localized with the nuclear spliceosomal protein SmB/B’ (Red) and DAPI (Blue).   
Co-localization of the HA-tagged AK045681 and the nuclear staining DAPI were 
observed in the Tuj1-positive neurons (bottom panels; Green: Tuj1, Red: HA, Blue: 








Additionally, the results revealed that there was a noticeable difference in the level of the 
translated proteins between the full-length and the spliced AK045681 (Figure 3-5).   
 
AK045681 was not a part of the spliceosome and was not involved  
in RNA splicing of GABA receptor and transporter genes 
Biological functions of the translatable AK045681 protein were examined.  The 
fact that AK045681was translatable in vitro and its protein was localized in the nucleus 
of the neurons led me to look at the potential function of AK045681 as a spliceosomal 
protein.  As stated earlier, the amino acid sequence of AK045681 is similar to the 
sequence of the spliceosomal U1C, which was shown to physically interact with another 
spliceosomal protein U1-70K.  Potential function(s) of the translated AK045681 protein 
as an alterative spliceosomal protein to U1C in the spliceosomal complex were examined.  
Co-immunoprecipitation of HA-tagged AK045681 to U1-70K in HEK293T cells 
revealed no physical association between the two proteins, which indicated AK045681 
was not the part of the spliceosome (Figure 3-5).     
The expression of AK045681 in the GABAergic neurons led me to look at the 
mRNA splicing activity of the GABA receptor and transporter genes. The results of RT-
PCR showed normal RNA splicing profiles for GABA receptor and transporter genes 
(Figure 3-5). Therefore, AK045681 was not involved in mRNA splicing of the GABA 






Figure 3- 5. Biochecial analyses of AK045681.  In vitro translation of a full-length 
cDNA (FL) and alterantive isform (AI) of AK045681 (Top panel). The ORF of 
AK045681 was translated as control (C).  (Middle panel): mRNA profiles of GABA 
receptors genes (Middle panel).  Co-immunoprecipitation of HA-tagged Ak045681 
protein with the nuclear spliceosomal protein U1 snRNP70 (Bottom panel).        
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Spatial and motor learning is intact in AK045681 mutant mice 
AK045681 KO mice are viable.  Nissl staining showed that gross brain 
morphology of AK045681 appeared to be normal (data not shown). The timing (postnatal 
day 12) and major locations (the hippocampus, the cerebellum and the amygdala) of the 
gene expression in the brain suggested that AK045681 might be involved in regulating 
learning, memory and other behaviors.  The metric and the topological spatial learning 
task were used to examine the function of the hippocampus.  As Figure 3-6 shows, there 
is no significant difference in time that both AK-KO mice and their WT littermate 
explored the novel objects in the metric and the topological spatial processing tasks.     
Rota-rod motor learning task was used to assess the function of the cerebellum in 
AK045681 mutant mice.  There was no significant difference in the average latency to 
fall off the rod between the AK045681 mutant and the WT littermate mice in each trail of 
every training days (Figure 3-7).  The average latency to fall off the rod in each day 
between the AK045681 mutant and the WT littermate mice was compared, and there was 
no significant difference between the groups (Figure 3-7).  These results indicate that the 
functions of the hippocampus and the cerebellum are intact in the AK 045681 mutant 
mice.      
 
Disruption of AK0456821 interferes anxiety-related behaviors  
AK045681 is strongly expressed in the limbic system such as the hippocampus 
and the amygdala.  It has been shown that the limbic system plays crucial roles in 
regulating fear-related behaviors including the anxiety behavior.  We subjected the 




Figure 3- 6. Spatial (hippocampal-dependent) are intact in AK045681 null mutant 
mice.  Mean time that AK-KO mice and their WT littermates interacted with the 
novel objects on the testing arena during a 15 minute habituation and a 5 minute 
testing session in metric spatial task (Top).  Mean time that AK-KO mice and their 
WT littermates interacted with the novel objects on the testing arena during a 15 
minute habituation and a 5 minute testing session in the topological spatial task 






























































Figure 3-7. Mean time latency to fall off the rod between the AK-KO mice and their 
WT littermate mice during a single 5 minute-trail in each day in the Rota-rod task 
(Top).  Mean time latency to fall off the rod between the AK-KO mice and their WT 
littermate mice during each single 5 minute-trail in the Rota-rod task (Bottom).  


















































WT	  (n=11)	  KO	  (n=12)	  
	  	  
108	  
examine the functions of the limbic system.  There was no difference in the total number 
of arm entries during a single 5-minute session between the AK045681 KO and their WT 
littermate mice.  When the time spent in each arm was compared, the AK045681 KO 
mice spent significantly more time in the open arms than their WT littermate mice did.  
On the contrary, the AK045681 KO mice spent significantly less time in the closed arms 
than their WT littermate mice did (Figure 3-8).  There was no significant difference in the 
time spent in the intersection between the AK045681 mutant and their WT littermate 
mice (Figure 3-8).  Finally, there was no significant difference in the distance travelled in 
the closed arms and the intersection between the AK045681 KO and their WT littermate 
mice.  However, when the distance travelled in the open arms between the AK045681 
mutant mice and their littermate mice was compared, the AK045681 KO mice traveled 
significantly more distance in the open arm than their WT littermate mice did (Figure 3-
8).  The results showed that the AK045681 mutant mice showed significantly less anxiety 
than their WT littermate mice, and disruption of the AK045681 impairs the regulation of 
anxiety-related behavior in mice.     	  
Discussion 
Characterization of the novel gene AK045681 was described in this study.  The 
results presented here demonstrated that the novel gene AK045681 was postnatally 
expressed in the GABAergic neurons in the specific regions of the brain such as the 
hippocampus, the amygdala, the cortex, and the hypothalamus. The AK04568 null 
mutant mice showed reduced levels of the anxiety-related behavior in the elevated plus 






Figure 3- 8. AK null mutant mice showed significant reduction of expression of 
anxiety-related behavior.    Mean time that the AK-KO mice and their WT 
littermate mice spent in each arms (open, closed, or intersection) during a 5 minute-
test in the elevated plus maze task (Top panel).  Mean distance that AK-KO mice 
and their WT littermate mice traveled in each arms during a single 5 minute-test in 
the elevated plus maze (Middle panel).  Mean number of entries that AK-KO mice 
and their WT littermate mice made into each arm during a single 5 minute-test in 
the elevated plus maze (Bottom panel).  N=9 and 7 for the AK-KO mice and the WT 
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related behavior through the GABA-mediated neurotransmission.  Imaging studies in 
humans, as well as lesion and microinfusion studies in animals, have indicated that brain 
regions such as the hippocampus, the amygdala, the cortex, and the hypothalamus were 
crucial neuronal substrates for regulation of fear and anxiety behaviors (Charney & 
Drevets, 2002). Pharmacological evidence has suggested that endogenous GABA plays a 
key role in regulation of anxiety since the drugs that altered GABAergic 
neurotransmission, such as benzodiazepepines, have been successfully managing the 
symptoms of anxiety disorders in humans (Goman et al., 2002; Mohler, 2007; Clement et 
al., 2002).  Furthermore, evidence from the knockout and transgenic mice that exhibited 
abnormal levels of anxiety-related behaviors supported the potential role of GABA-
mediated neurotransmission in the pathophysiology of anxiety. For instance, the mice 
with the gamma2 subunit of GABAa receptor mutation showed increased anxiety 
behavior in both the elevated plus maze and the light and dark transition task.  Alternative 
splicing creates two forms of transcripts of the gamma2 subunit of GABAa receptor, γ2L 
and γ2s.  Interestingly, the mice with the mutation of γ2L of GABAa receptor showed an 
increase in anxiety behavior in the elevated plus maze task (Mohler, 2007; Clement et al., 
2002).  The mice deficient in the GABA-synthetic gene, GAD-65, showed a reduction in 
GABA neurotransmission and exhibited increased levels of anxiety-related behavior in 
the elevated plus maze and the light and dark transition task (Kash et al., 1999).  The 
GAD-65 knockout mice were also less sensitive to the acute effects of benzodiazepepines 
and barbiturates (another positive modulator of GABAergic neurotransmission) (Kash et 
al., 1999).  In addition, GAD-65 has been associated with the panic disorder-related trait 
of behavioral inhibition in children (Smoller et al., 2001).    
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Amino acid sequence similarity of this novel gene to the spliceosomal protein 
U1C suggests that functional roles of this novel gene may be RNA splicing.  AK045681 
may be a part of the major spliceosome or a splicing factor to regulate RNA splicing and 
maturation.  Furthermore, the potential function of AK045681 in RNA splicing and 
maturation may be activity-dependent.  It has been reported that some neuronal genes 
such as BDNF produce multiple forms of its proteins in the activity-dependent manners 
(e.g. when some specific learning occurs) by utilizing the alternative splicing mechanism 
(reviewed in Li et al., 2007).  I hypothesized that AK045681 might be involved in RNA 
splicing and maturation (either activity-dependent or not) of the genes in GABA-
mediated neurotransmission.  Therefore, the disruption of the splicing mechanism in the 
brain regions such as the hippocampus, the amygdala, the cortex and the hypothalamus 
could interfere with the regulation of anxiety-related behavior.   
To test this hypothesis, three molecular requirements to be a part of the 
spliceosome were examined.  First, since mRNA splicing takes place in the nucleus of the 
cells, the protein of this novel gene should be localized in the nucleus of the neurons if 
the function of AK045681 was RNA splicing as suggested.   The results showed the co-
localization of the immune-tagged (HA) AK045681 protein and the nuclear DAPI 
staining in the neurons.  This novel protein was indeed localized in the nucleus of the 
neurons.  Nuclear co-localization of AK045681 with the spliceosomal proteins further 
indicates that AK045681 might be involved in RNA splicing in the nucleus of the 
neurons.  Indeed, AK045681 co-localized the spliceosomal protein, SmB/B’/N with the 
HA-tagged AK045681 protein in the nucleus of the neurons, as the results presented have 
showed.     
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Ultimately, if AK045681 is an activity-dependent alternative RNA splicer, 
AK045681 might show a physical interaction (or binding) with the spliceosomal proteins.  
Because the amino acid sequence of this novel gene is similar to the spliceosomal protein 
U1C, AK045681 might form the spliceosome complex and function as U1C does. In the 
spliceosome complex, U1C physically interacts with the spliceosomal proteins U1-70K 
and SmB/B’/N to recognize a 5’ splice site (Bedford et al., 1997).   Furthermore, if 
AK045681 is truly an alternative splicer, the target gene(s) that AK045681 alternatively 
splice may be the gene(s) playing roles in GABA-mediated neurotransmission. Thus, 
potential roles of AK045681 in a part of the spliceosome as an alternative part for U1C, I 
examined the physical interaction of AK045681 with the spliceosomal proteins U1-70K 
or SmB/B’/N by co-immunoprecipitation.  In addition, alternative splicing mRNA 
profiles of the GABA receptors and transporters genes were also analyzed to test this 
hypothesis.  As the results presented here, however, AK045681 did not interact with 
either spliceosomal proteins, and it appeared to be normal mRNA splicing profiles of 
these genes between the AK045681 mutant mice and their wild-type littermates.  
Alternative splicing created two transcripts of AK045681.  The full-length of 
AK045681 consisted of exon1 through 4, whereas the isoform was made of only exon1 
and exon4.  The difference between those transcripts of AK045681 lay in 5’ untranslated 
region (5’UTR) of the gene; short 5’UTR (~900-bp) for the spliced and long 5’UTR 
(~1100-bp) for the full-length transcript.  As the results displayed, the spliced transcripts 
with the short 5’UTR translated efficiently, while the full-length transcripts with the long 
5’UTR poorly translated when both AK045681 transcripts were translated in vitro.  It has 
been reported that the genes yield mRNAs containing distinct 5’UTRs, and those distinct 
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5’UTRs function as translation regulators in vivo.  RUNX1 is a member of the runt 
domain transcription factors that plays critical regulatory roles in hematopoiesis and 
osteogenesis (Kumano & Kurokawa, 2010:Ito & Miyazono, 2003:Speck, 2001).  
RUNX1is expressed through two promoters known as distal (D) and proximal (P), which 
produce two different 5’UTRs (D-UTR and P-UTR) (Ghozi et al., 1996).  When D-UTR 
and P-UTR were translated in vivo, P-UTR and D-UTR were equally translated.  The 
longer P-UTR was found to be weakly translated, while the shorter D-UTR was strongly 
translated (Pozner et al., 2000).  The difference in the translation efficiency is due to the 
length and cis-elements that lie in each UTR.  Translation through D-UTR was found to 
be cap-dependent in contrast P-UTR was facilitated through cap-independent and internal 
ribosomal entry site (IRES)-dependent translation (Pozner et al., 2000).  It has been 
suspected that IRES-mediated translation could be a part of regular translation 
mechanism; however, mRNA with IRES could be translated only under certain cellular 
circumstances, such as growth arrest, serum starvation, γ-irradiation, hypoxic condition, 
where cap-dependent translation is stalled (Holick et al., 1999; Rhoads, 1993; Song et al., 
1999).  One could speculate that AK045681 would utilize a similar mechanism to ensure 
its gene expression under any biological circumstance.              
The timing and pattern of AK045681 expression may be useful in terms of 
genetic engineering.  As stated earlier, this novel gene is turned only on postnatally and 
its expression persists throughout adulthood.  Furthermore, AK045681 is only expressed 
in the GABAergic neurons in the specific neuronal regions including the hippocampus 
and the amygdala.  There are a few Cre drivers that truly perform the recombination only 
in the postnatal day. AK045681 may be a terrific gene to be utilized as a postnatal 
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neuronal-specific Cre driver.  Because AK045681 is only expressed in GABAergic 
neurons in the brains, this will add more specificity for its usage as a postnatal neuronal-
specific Cre driver.   
The biological functions of AK045681 still remain unknown.  To uncover the 
biological role of AK045681 will provide valuable information to the genetic and 
molecular mechanisms of anxiety regulation.            
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Chapter 2 dealt with the challenge of transferring a large chromosomal fragment 
between different species.  It was attempted to develop the technology that enables us to 
move the chromosomal fragment from canine fibroblasts to mouse ES cells.   As a model, 
the canine QTL that inversely regulates length and width of the femur growth was used.  
As stated in Chapter 2, there were two biological obstacles to overcome in order to 
achieve this objective.  The first biological obstacle was to perform gene targeting in the 
canine somatic cells.  The second biological obstacle was to pass the targeted canine 
chromosome with the QTL of interest through the cell membrane of the mouse ES cells.  
The first obstacle was exclusively dealt with in Chapter 2.  The results presented in 
Chapter 2 showed that the targeting vector was indeed introduced into the canine 
immortalized fibroblasts, yet not targeted into the QTL correctly.  Conventionally, gene 
targeting has been done in ES cells.  However, availability of ES cells for each specie is 
limited.  In those species without ES cells, gene targeting in the immortalized cells has 
been tried and improved.  It has been shown that the immortalized cells can be targeted 
when the nuclear localization signaling sequence is incorporated into the targeting 
vectors (Bashir & Piedrahita, 2004; Meehan, et al., 2008).  Additionally, it has been 
reported that homologous recombination occurs mainly in the late S/G2 phase and that 
targeting efficiency is enhanced in S-phase-synchronized cells by thymidine treatment 
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(Takata et al., 1998; Lundin et al., 2002).  Thymidine can trap cells into the G1/S-phase of 
cell cycles and the cell cycles can be synchronized in the majority of cells.  When 
thymidine is removed from the cells, the cells are then allowed to proceed cell cycle 
through S-phase in a synchronized manner, which is when the synchronized cell should 
be transfected with the targeting vectors by electroporation.    For a future project, the 
immortalized canine fibroblasts may be electroporated with the targeting vector 
containing the nuclear localization sequences combination of the cell cycle to see if the 
proper targeting can be achieved.   
Gene targeting has been efficiently performed in mouse ES cells since this 
revolutionary genetic technology was invented.  It has been reported that gene targeting 
has been successfully accomplished in ES cells and iPS cells from other species (Tong et 
al., 2010; Zou et al., 2009).  Because canine ES cells carrying this specific QTL were 
unavailable, I attempted to make iPS cells from adult canine fibroblasts by using 
lentiviral and the piggybac transposon iPSC vectors.  The results showed that partial iPS 
cells could be generated from the canine adult fibroblasts.  However, those partial iPS 
cells were never reprogrammed into fully reprogrammed iPSCs.  The major problem 
must be addressed to generate canine iPSCs and further succeed in gene targeting.  One is 
the age of our canine fibroblasts.  It has been demonstrated that the reprogramming is 
more difficult if the host cells are differentiated further along with the cell fates (Eminli 
et al., 2009).  In this project the adult and neonatal canine fibroblasts were used for the 
canine iPSC formation.  As the results showed, even the neonatal fibroblasts had 
difficulty to pass the initiation phase of iPSC generation.  Thus, developmentally 
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immature canine cells (i.e., progenitors or embryonic cells of any cell types) with the 
QTL of interest should be reprogrammed to create the canine iPSCs.   
The other major problem is compatibility of the mouse or human-derived 
reprogramming factors.  In this study the mouse and human-derived reprogramming 
factors (Oct4, Sox2, Klf4 and c-Myc) were used to generate the canine iPSCs.  Although 
those four factors from either species were sufficient to generate iPS cells from any 
species except dogs, both mouse and human-derived reprogramming factors may not be 
compatible to activate the canine reprogramming machinery.  In fact, a recent report 
demonstrated that canine iPS cell could be generated from the embryonic fibroblasts by 
using canine Oct4, Sox2, Klf4 and c-Myc in combination with small molecule inhibitors 
(Shimada et al., 2010).  Thus, the canine-derived reprogramming factors may be required 
to generate the canine iPSCs.  Collectively, reprogramming the developmentally 
immature cells such as the embryonic fibroblasts by the canine-derived four stem cell 
factors may be tried to successfully generate the canine iPSCs and further achieve gene 
targeting in the canine cells. 
In Chapter 3 the random mutagenesis of mouse genome by piggybac DNA 
transposon system provided the opportunity to characterize the novel gene, AK045681, 
expressed in mouse brain.  The results showed that this gene is expressed specifically in 
neurons and the expression started only postnatally (at postnatal day 12).  This gene is 
expressed in specific regions of the brain such as the limbic system (hippocampus and 
amydgala), neocortex, the cerebellum and olfactory system (olfactory bulb and anterior 
olfactory nucleus). Further analyses revealed that the gene is mainly expressed in 
GABAnergic neurons with an exception of granular cells in the cerebellum. Cellular 
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localization of the gene product was found to be nuclear and the gene was indeed 
translated in vitro.  The timing of gene expression of this gene and no morphological 
deficit in the mutant brain suggested that the phenotypes might be found in behavior.  
Three behavioral tests were performed to identify phenotypes; 1) Metric and topological 
spatial learning task to check function of hippocampus; 2) Rota rod task to examine the 
cerebellar function; 3) Elevated plus maze to see normal anxiety behavior, which is 
regulated by the limbic system.  The results of behavioral analyses showed that the 
mutant mice were less anxious or fearful than the wild type mice, which indicated that the 
gene might play a role in regulating the anxiety behavior in limbic system.   
Based on the amino acid sequence similarity to spliceosomal protein U1C, the 
gene may be involved in RNA splicing.  I hypothesized that the gene might be a 
component of the spliceosome or a splicing factor that is required to do alternative 
splicing for specific genes.  Since the gene is expressed mainly in the GABAergic 
neurons, the gene might be involved in the alternative splicing of GABA receptors and 
transporters.  Co-immunoprecipitation of the gene with the spliceosomal proteins 
(SmB/B’/N and U1-70K) was performed.  Both spliceosomal proteins were key 
components of the spliceosome, and these proteins have shown to physically interact with 
U1C, whose amino acid sequence is similar to that of AK045681. However, Co-
immunoprecipitation experiment revealed that AK did not physically interact with either 
spliceosomal proteins.  Moreover, RT-PCR showed that all GABA receptors and 
transporter genes seemed to be spliced normally.  Thus, the functions of AK045681 
remain unknown.  There are a few experiments to identify the functional roles of this 
gene as future directions of the project; 1) Immunopreiciptation of HA-tagged AK045681 
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to isolate binding partner(s) and mass spectrometry to identify the binding partner(s); 2) 
Co-immunoprecipitation of HA-tagged AK045681 with the identified binding partner to 
prove their physical association; 3) RNA-Seq to characterize the transcriptosome of 
neurons between the wild type littermate mice and the mutant mice, focusing on the 
information of splicing variants of known genes because biological function of 
AK045681 may be RNA splicing based on amino acid sequence similarity to U1C (Wang 
et al., 2009; Ozsolak & Milos, 2010; van der Brug et al., 2010).  The further analyses of 
AK045681 mutant mice will provide additional information about the biology of anxiety-
related behaviors and will potentially serve as the mouse model of the anxiety-related 
behaviors.  Furthermore, the specific location and timing of AK045681 expression will 
be certainly utilized as a genetic tool including a postnatal neuronal specific Cre-driver.     
 
References 
Arbones, M.L., Austin, H.A., Capon, D.J. and Greenburg, G. (1994). Gene targeting in 
normal somatic cells: inactivation of the interferon-gamma receptor in myoblasts.  Nature 
Genet., 6, 90-97. 
 
Bashir, M. and Piedrahita, J.A. (2004). Nuclear localization signal and cell synchrony 
enhance gene targeting efficiency in primary fetal fibroblasts.  Nucleic Acids Res., 32, 
e25. 
 
Brown, J.P., Wei, W. and Sedivy, J.M. (1997). Bypass of senescence after disruption of 
p21CIP1/WAF1 gene in normal diploid human fibroblasts.  Science, 277, 831-834. 
 
Eminli, S., Foudi, A., Stadtfeld, M., Maherali, N., Ahfeldt, T., Mostoslavsky G., Hock, H. 
and Hochedlinger K. (2009).  Differentiation stage determines potential of hematopoietic 
cells for reprogramming into induced pluripotent stem cells.  Nat. Genet., 41, 968-978. 
 
Hanson, K.D. and Sedivy, J.M. (1995). Analysis of biological selections for high-
efficiency gene targeting.  Mol. Cell. Biol., 15, 45-51. 
 
	   125	  
Lundin, C., Erixon, K., Arnaudeau, C., Schultz, N., Jenssen, D., Meuth, M. and Helleday, 
T. (2002). Different roles for nonhomologous end joining and homologous recombination 
following replication arrest in mammalian cells.  Mol. Cell. Biol., 22, 5869-5878. 
 
Ozsolak, F. and Milos, F. (2010) RNA sequencing: advances, challenges and 
opportunities.  Nat. Rev. Genet., 12, 87-98. 
Shimada, H., Nakada, A., Hashimoto, Y., Shigeno, K., Shionoya, Y. and Nakamura, T. 
(2010) Generation of Canine induced pluripotent stem cells by retroviral transduction and 
chemical inhibitors.  Mol. Reprod. Dev., 77, 1-2. 
 
Takata, M., Sasaki, M.S., Sonda, E., Morrison, C., Hashimoto, M., Utsumi, H., 
Yamaguchi-Iwai, Y., Shinohara, A. and Takeda, S. (1998). Homologous recombination 
and nonhomologous end-joining pathways of DNA double-strand break repair have 
overlapping roles in the maintenance of chromosomal integrity in vertebrate cells.  
EMBO J., 17, 5497-5508. 
 
Tong, C., Li, P., Wu, N.L., Yan, Y. and Ying, Q-L. (2010). Production of p53 gene 
knockout rats by homologous recombination in embryonic stem cells.  Nature. 467, 211-
213. 
 
van der Brug, M., Nalls, M.A. and Cookson, M.R. (2010) Deep sequencing of coding and 
non-coding RNA in CNS.  Brain Res., 1338, 146-154.  
 
Waldman, A.S. (1992). Targeted homologous recombination in mammalian cells.  Crit. 
Rev. Oncol. Hematol., 12, 49-64. 
 
Wang, Z., Gerstein, M. and Snyder, M. (2009) RNA-Seq: a revolutionary tool for 
transcriptomics.  Nat. Rev. Genet., 10, 57-63. 
 
Zou, J., Maeder, M.L., Mali, P., Pruett-Miller, S.M., Thibodeau-Beganny, S., Chou, B-
K., Chen, G., Ye, Z., Park, I-H., Daley, G.Q., Porteus, M.H., Joung, J.K. and Cheng L. 
(2009). Gene targeting of a disease-related gene in human induced pluripotent stem and 






   
   
 
